

Prior Authorization Requirements

Effective 01/01/2025

# acromegaly therapy

**Products Affected**

- SOMAVERT

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Documentation of diagnosis including supporting lab/diagnostic test results.<br>Documentation of all past treatments for acromegaly.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | For Acromegaly, must be prescribed by an Endocrinologist.   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for the treatment of acromegaly in patients who have had inadequate response to surgery or radiation and have had inadequate response with generic injectable octreotide. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# acthar

---

## Products Affected

- ACTHAR
- ACTHAR SELFJECT
- CORTROPHIN GEL

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | For all FDA approved indications in adults, documentation of contraindication to, serious side effects (such as steroid-induced mania or sepsis) from, or therapeutic failure with oral or injectable corticosteroids is required. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# actimmune

---

## Products Affected

- ACTIMMUNE

| <b>PA Criteria</b>                  | <b>Criteria Details</b>   |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# actinic keratosis

---

## Products Affected

- *diclofenac sodium topical gel 3 %*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a Dermatologist or Oncologist   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for the diagnosis of actinic keratoses in patients who have had previous trial and failure or severe intolerance with generic imiquimod 5% cream and either generic fluorouracil 5% cream or generic fluorouracil solution. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# acute hae

---

## Products Affected

- *icatibant*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Excluded for the prophylaxis of hereditary angioedema attacks.  |
| <b>Required Medical Information</b> | UNDER CMS REVIEW  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by allergist, immunologist, hematologist, or dermatologist   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for a confirmed diagnosis of HAE Type 1, Type II, or Type III for the treatment of acute hereditary angioedema attacks. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# alpha-1 antitrypsin therapy

---

## Products Affected

- PROLASTIN-C INTRAVENOUS SOLUTION

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Documentation of diagnosis, pertinent lab/diagnostic test results (such as AAT serum levels, genotype testing, and pulmonary function testing, or other tests performed to confirm the diagnosis, and documentation of previous therapies |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a pulmonologist   |
| <b>Coverage Duration</b>            | One year, only as weekly infusions  |
| <b>Other Criteria</b>               | UNDER CMS REVIEW  |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# amphetamine

---

## Products Affected

- *amphetamine sulfate*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Excluded when used for weight loss, even if non-cosmetic (such as morbid obesity).  |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# apomorphine

---

## Products Affected

- *apomorphine*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling   |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist.   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Apomorphine (generic for Apokyn) is covered for the treatment of off episodes in Parkinson's disease patients established on levodopa/carbidopa therapy. Patient must have documented attempts at levodopa/carbidopa dose and/or frequency adjustment, up to a maximum tolerated dose is achieved or intolerance is experienced, to mitigate wearing-off symptoms. Recertification for the treatment of off episodes will require objective and/or subjective evidence from prescriber of a decrease in frequency and/or severity of wearing-off symptoms. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |



# arcalyst

---

## Products Affected

- ARCALYST

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# arikayce

## Products Affected

- ARIKAYCE

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Excluded when used for the treatment of patients with non-refractory mycobacterium avium complex (MAC) disease or when being used as a single agent.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies, pertinent lab/diagnostic test results. For the diagnosis of refractory mycobacterium avium complex disease, sputum culture results are required.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an infectious disease specialist or pulmonologist.   |
| <b>Coverage Duration</b>            | Initial approval - 6 months. Recertifications - 1 year.  |
| <b>Other Criteria</b>               | Covered for patients with refractory mycobacterium avium complex (MAC) disease who have documentation of a positive sputum culture, obtained after a minimum 6-month treatment with a multi-drug regimen (such as clarithromycin/azithromycin, rifampin, and ethambutol). For approval, patient must be using Arikayce in combination with other medications as part of a multi-drug regimen. Recertification will require documentation of a negative sputum culture while taking Arikayce taken within 30 days prior to the request. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# austedo

## Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG      24-H ER TAB DOSE PACK 12-18-24-30 MG, 6
- AUSTEDO XR ORAL 24-H ER TAB 12 MG, 18      MG (14)-12 MG (14)-24 MG (14)
- MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6
- MG
- AUSTEDO XR TITRATION KT(WK1-4) ORAL

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Will not be covered in combination with tetrabenazine (Xenazine).   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist or a psychiatrist   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# behavioral health

## Products Affected

- *asenapine maleate* 20-10 MG, 5-10 MG
- AUVELITY
- CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG
- FANAPT
- LYBALVI ORAL TABLET 10-10 MG, 15-10 MG,
- REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG
- SECUADO
- VRAYLAR ORAL CAPSULE
- VRAYLAR ORAL CAP, DOSE PACK

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling. Lybalvi also excluded for patients using opioids or undergoing acute opioid withdrawal.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | For a dx of bipolar disorder, coverage of asenapine (generic for Saphris), Caplyta, or Vraylar requires documentation of significant intolerance or therapeutic failure of two generic first-line treatments (such as lithium, valproate, aripiprazole, risperidone, olanzapine, ziprasidone, quetiapine). For a dx of schizophrenia, coverage of asenapine (generic for Saphris), Caplyta, Fanapt, Rexulti, Secuado, or Vraylar requires documentation of significant intolerance or therapeutic failure of two generic first-line treatments (such as lurasidone, lithium, valproate, aripiprazole, risperidone, olanzapine, ziprasidone, quetiapine). Coverage of Lybalvi for a dx of schizophrenia or bipolar 1 disorder requires documentation of one of the following: 1) at least a 4-week trial with generic olanzapine that yielded beneficial stable clinical response but unacceptable weight gain (unacceptability as determined by provider with attribution to side effect of olanzapine) or 2) significant intolerance or therapeutic failure of two generic first-line treatments (such as lurasidone, lithium, valproate, aripiprazole, risperidone, olanzapine, ziprasidone, quetiapine). For a dx of major depressive disorder, coverage of Auvelity, Rexulti, or Vraylar requires documentation of significant intolerance or therapeutic failure of an antidepressant (such as an SSRI, SNRI, TCA, bupropion) and a generic atypical antipsychotic indicated for major depressive disorder (such as aripiprazole, olanzapine, quetiapine), used alone or in combination. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |

| PA Criteria            | Criteria Details |
|------------------------|------------------|
| Part B<br>Prerequisite | No               |

# benlysta

---

## Products Affected

- BENLYSTA SUBCUTANEOUS

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Excluded for patients who are currently receiving treatment with any B-cell-targeted therapy or biologic.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be followed by a Rheumatologist or Nephrologist   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy and patients with active lupus nephritis who are receiving standard therapy. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# besremi

---

## Products Affected

- BESREMI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling. If patient is currently taking hydroxyurea, they must transition off by gradual taper and discontinue by week 13.  |
| <b>Required Medical Information</b> | UNDER CMS REVIEW   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an oncologist or hematologist.   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of polycythemia vera (PV). Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# bexarotene gel

---

## Products Affected

- *bexarotene topical*

| <b>PA Criteria</b>                  | <b>Criteria Details</b>   |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an oncologist or dermatologist.   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for a diagnosis of refractory or persistent cutaneous t-cell lymphoma (CTCL) (stage 1a or 1b) after failure with or inability to tolerate at least one other therapy. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |



# BOTOX

---

## Products Affected

- BOTOX

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | PATIENT PROGRESS NOTES, DOCUMENTATION OF DIAGNOSIS AND DOCUMENTATION OF ANY PREVIOUS THERAPIES  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | ONE YEAR  |
| <b>Other Criteria</b>               | REQUESTS WILL BE EVALUATED FOR PART B VS PART D COVERAGE. REQUESTS FOR NON-FDA APPROVED INDICATIONS WILL BE EVALUATED ACCORDING TO THE MEDICARE STATUTORY OFF LABEL USE REQUIREMENTS. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# BRAF/MEK

## Products Affected

- BRAFTOVI
- COTELLIC
- MEKINIST ORAL RECON SOLN
- MEKINIST ORAL TABLET 0.5 MG, 2 MG
- MEKTOVI
- TAFINLAR ORAL CAPSULE
- TAFINLAR ORAL TABLET FOR SUSPENSION
- ZELBORAF

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | For cancer diagnosis, must be prescribed by an oncologist or hematologist, or urologist in the case of prostate cancer. For non-cancer diagnosis, must be prescribed by an appropriate specialist. |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements.  |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# BTKi

---

## Products Affected

- BRUKINSA
- CALQUENCE
- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET 420 MG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | UNDER CMS REVIEW  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | For cancer diagnosis, must be prescribed by an Oncologist or Hematologist. For non-cancer diagnosis, must be prescribed by an appropriate specialist. |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | UNDER CMS REVIEW  |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# budesonide foam

---

## Products Affected

- *budesonide rectal*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a gastroenterologist  |
| <b>Coverage Duration</b>            | Initial approval - 6 weeks. Subsequent courses will be authorized at 6-week intervals.  |
| <b>Other Criteria</b>               | Budesonide foam will be authorized for patients with a diagnosis of active, mild to moderate ulcerative colitis with documentation of severe intolerance or therapeutic failure to mesalamine enemas, mesalamine suppositories, or hydrocortisone enemas. The initial approval will be for six weeks. As topical budesonide does not have proven efficacy to maintain remission, chronic therapy with budesonide foam will not be authorized. Approval for future treatment courses will require documentation of remission from the initial course of therapy. In addition, documentation that remission failed on a course of an appropriate immunomodulator or biologic will be required. If the criteria are met, subsequent treatment courses will be approved in 6-week intervals. Requests will also be evaluated for off-label use. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# bylvay

## Products Affected

- BYLVAY

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | History of liver transplant, clinical evidence of decompensated cirrhosis or as limited by FDA labeling  |
| <b>Required Medical Information</b> | Diagnosis of Alagille syndrome or PFIC confirmed by genetic testing, objective and/or subjective provider assessment of baseline pruritus severity.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a hepatologist, gastroenterologist, or physician knowledgeable in the management of progressive familial intrahepatic cholestasis (PFIC).  |
| <b>Coverage Duration</b>            | Initial approval - 6 months. Recertifications - 1 year.  |
| <b>Other Criteria</b>               | Covered for the treatment of cholestatic pruritus in patients at least 12 months of age who have Alagille syndrome with confirmed mutations in the JAG1 or NOTCH2 gene. Covered for treatment of significant pruritus due to progressive familial intrahepatic cholestasis (PFIC). Significant is defined as severe enough pruritus that sleep and/or activities of daily living are disturbed. Recertification for both indications requires documentation that the patient is tolerating therapy and is experiencing a decrease in pruritus from baseline based on objective and/or subjective assessment from provider. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# cablivi

---

## Products Affected

- CABLIVI INJECTION KIT

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a hematologist  |
| <b>Coverage Duration</b>            | Initial approval - 3 months. Recertification - 1 month.   |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) when being used in combination with plasma exchange and immunosuppressive therapy (such as systemic corticosteroids or rituximab). Should documentation of underlying disease persist (such as suppressed ADAMTS13 activity levels) after the initial treatment period (up to 30 days beyond the last plasma exchange), recertification will be approved for an additional 1 month of therapy. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# camzyos

## Products Affected

- CAMZYOS

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a cardiologist.  |
| <b>Coverage Duration</b>            | 6 months   |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of symptomatic obstructive hypertrophic cardiomyopathy (HCM) confirmed by echocardiogram AND/OR cardiac magnetic resonance. Must have New York Heart Association (NYHA) Class II or Class III functional status and a left ventricular ejection fraction (LVEF) of at least 55%. In addition, the patient must have had serious side effects or drug failure to at least one non-vasodilating beta blocker (i.e. atenolol, bisoprolol, metoprolol) AND one non-dihydropyridine calcium channel blocker (must be separate trials), unless there is a documented medical reason why these agents cannot be used. Recertification will require 1) submission of progress notes documenting the patient has achieved/maintained a positive clinical response to therapy AND 2) the patient's LVEF is at least 50%. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# carbaglu

---

## Products Affected

- *carglumic acid*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for acute or chronic hyperammonemia due to the deficiency of the hepatic enzyme n-acetylglutamate synthase (NAGS). Covered as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |



# CDK 4/6

## Products Affected

- IBRANCE
- KISQALI
- KISQALI FEMARA CO-PACK ORAL TABLET  
200 MG/DAY(200 MG X 1)-2.5 MG, 400  
MG/DAY(200 MG X 2)-2.5 MG, 600
- VERZENIO

MG/DAY(200 MG X 3)-2.5 MG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | UNDER CMS REVIEW  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an oncologist or hematologist.  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Coverage of Ibrance/palbociclib requires documentation of severe intolerance to or contraindication with Kisqali/ribociclib and Verzenio/abemaciclib. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# cerdelga

## Products Affected

- CERDELGA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Combination therapy with Cerdelga and enzyme replacement therapy (such as Eleyso, Cerezyme) is excluded. Concomitant use of a moderate or strong CYP2D6 inhibitor with a moderate or strong CYP3a inhibitor in extensive metabolizers or intermediate metabolizers is excluded. Concomitant use of a strong CYP3a inhibitor in poor metabolizers or intermediate metabolizers is excluded. Cerdelga is excluded in patients with pre-existing cardiac disease, long Q-T syndrome, and for those who take class 1a or class III antiarrhythmic. |
| <b>Required Medical Information</b> | Diagnosis, including supporting labs/diagnostic test results (such as enzyme analysis, mutation analysis, or bone marrow studies, or other tests performed to confirm the diagnosis). Current drug profile to avoid labeled exclusions for use with enzyme replacement therapy, strong CYP3a inhibitors, and certain antiarrhythmics.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Cerdelga is covered for Type 1 Gaucher disease in patients who are CYP2D6 extensive metabolizers, intermediate metabolizers or poor metabolizers.  |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# cgrp antagonists

---

## Products Affected

- AJOVY AUTOINJECTOR
- AJOVY SYRINGE

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | Initial approval - 6 months. Recertifications - 1 year.  |
| <b>Other Criteria</b>               | Covered for a diagnosis of episodic or chronic migraine headache. Patient must be experiencing 4 or more migraine headache days per month. Patient must have been treated with two different classes of medications, for at least eight weeks per trial, that are supported by compendia for the prophylactic treatment of migraine headache (such as amitriptyline, divalproex sodium, propranolol, topiramate, or venlafaxine) which resulted in intolerance or lack of clinical efficacy. For clinical failure due to intolerance, an eight-week trial of medication is not required. Upon recertification, prescriber must attest to the clinical response to treatment, defined as a reduction in the number of migraine headache days per month compared to pre-treatment. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# cholbam

## Products Affected

- CHOLBAM

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Documentation of diagnosis and pertinent lab/diagnostic test results (such as gas chromatography-mass spectrometry urine analysis, liver function tests and other tests performed to confirm the diagnosis).   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an endocrinologist, gastroenterologist, geneticist, hepatologist, or metabolic specialist.   |
| <b>Coverage Duration</b>            | Initial approval - 3 months. Recertifications - 1 year.  |
| <b>Other Criteria</b>               | For its FDA approved indications, there must be a diagnosis made by gas chromatography-mass spectrometry analysis of the urine with a positive identification of elevated bile acids. In addition, liver function tests must identify elevated serum aminotransferases with normal serum gamma glutamyltransferase. The initial approval will be for three months. After the initial three-month authorization, approval will be granted in one-year increments with documentation of improved liver function via aminotransferase lowering. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# CHORIONIC GONADOTROPIN

---

## Products Affected

- *chorionic gonadotropin, human intramuscular*
- PREGNYL

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | EXCLUDED WHEN USED TO PROMOTE FERTILITY   |
| <b>Required Medical Information</b> | DIAGNOSIS, CURRENT AND PREVIOUS THERAPIES USED FOR THE TREATMENT OF THE STATED DIAGNOSIS                                    |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | ONE YEAR  |
| <b>Other Criteria</b>               | REQUESTS FOR NON-FDA APPROVED INDICATIONS WILL BE EVALUATED ACCORDING TO THE MEDICARE STATUTORY OFF-LABEL USE REQUIREMENTS. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# CLOMIPHENE

---

## Products Affected

- *clomiphene citrate*

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Exclusion Criteria           | EXCLUDED WHEN USED TO PROMOTE FERTILITY   |
| Required Medical Information | Diagnosis   |
| Age Restrictions             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| Prescriber Restrictions      | None  |
| Coverage Duration            | ONE YEAR  |
| Other Criteria               | REQUESTS FOR NON-FDA APPROVED INDICATIONS WILL BE EVALUATED ACCORDING TO THE MEDICARE STATUTORY OFF-LABEL USE REQUIREMENTS. |
| Indications                  | All Medically-accepted Indications.   |
| Off Label Uses               |   |
| Part B Prerequisite          | No  |

# cosentyx

## Products Affected

- COSENTYX (2 SYRINGES)
- COSENTYX PEN (2 PENS)
- COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML
- COSENTYX UNOREADY PEN

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a dermatologist or rheumatologist   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for the diagnosis of ankylosing spondylitis in patients with refractory disease defined by failure of at least one NSAID at maximally tolerated dose taken for a minimum one-month duration. Covered for the diagnosis of moderate to severe chronic plaque psoriasis with psoriasis that involves at least 5% body surface area (BSA). Covered for the diagnosis of moderate to severe chronic plaque psoriasis in patients with psoriasis that involves less than 5% BSA if the affected area involves the hands, feet, facial or genital regions. Patients also must meet one of the following criteria: 1) had a 3-month trial of acitretin, methotrexate, or cyclosporine therapy resulting in intolerance or clinical failure or 2) have tried UVB/coal tar or PUVA/topical corticosteroids for at least 3 months or 3) have tried and failed at least two of the following for 3 months: treatment with medium and/or high potency topical corticosteroids or anthralin, calcipotriene, or tazarotene. Covered for a diagnosis of psoriatic arthritis. Covered for a diagnosis of non-radiographic axial spondyloarthritis. Covered for a diagnosis of moderate to severe hidradenitis suppurativa (HS). Covered for patients with a diagnosis of enthesitis-related arthritis who have failed to respond to and/or are intolerant to at least one month of maximally tolerated NSAID therapy. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# cuvrior

---

## Products Affected

- CUVRIOR

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of stable Wilson's disease who are de-coppered and tolerant to penicillamine. Must have contraindication to penicillamine tablets (generic for Depen) and contraindication to trientine capsules (generic for Syprine). Recertification requires evidence of provider re-evaluation showing that patient cannot be transitioned to maintenance on penicillamine tablets (generic for Depen) or trientine capsules (generic for Syprine). Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |



# daybue

---

## Products Affected

- DAYBUE

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling   |
| <b>Required Medical Information</b> | UNDER CMS REVIEW   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist or provider who specializes in the treatment of Rett Syndrome (RTT)  |
| <b>Coverage Duration</b>            | 6 months   |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of classic or typical Rett Syndrome (RTT) and have a confirmed mutation of the MECP2 gene. Recertification will require subjective or objective evidence from provider that the patient is tolerating therapy and the drug is providing ongoing benefit in terms of disease improvement or stability (i.e., symptoms, quality of life measures, and/or functional measures). Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# deflazacort

## Products Affected

- *deflazacort oral suspension*
- *deflazacort oral tablet 18 mg, 30 mg, 36 mg, 6 mg*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies for stated diagnosis, results of Duchenne Muscular Dystrophy (DMD) gene mutation study   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for all FDA approved indications with required documentation of significant side effects resulting from a minimum 3-month trial of oral prednisone. Examples of significant prednisone side effects include cushingoid appearance, central (truncal) obesity, undesirable weight gain, inability to manage diabetes or hypertension, steroid-induced mania, or sepsis. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# dichlorphenamide

---

## Products Affected

- ORMALVI

| <b>PA Criteria</b>                  | <b>Criteria Details</b>   |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist or geneticist.  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# dihydroergotamine

---

## Products Affected

- *dihydroergotamine nasal*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling. Excluded for prevention of migraines or cluster headaches.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a headache or pain specialist or neurologist  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for the acute treatment of migraine headache in patients with documented trial and failure or severe intolerance to two different generic triptans (any dosage form) used in combination with a non-opioid analgesic (such as aspirin, NSAID, or acetaminophen). Will not be approved for prophylactic therapy. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# dojolvi

## Products Affected

- DOJOLVI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, via appropriate molecular genetic testing confirming at least one known LC-FAOD mutation such as CPT1A, CPT2, ACADVL, HADHA, or HADHB. If molecular genetic testing is not definitive, then biochemical analysis showing diminished enzyme activity measured on skin fibroblasts must be provided. In addition to one of the above, plasma or dried blood spot acylcarnitine analysis showing a characteristic pattern consistent with LC-FAOD must be provided.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a metabolic disease specialist knowledgeable in disease-related dietary management.  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of one of the following long-chain fatty acid oxidation disorders (LC-FAOD): very long chain acyl-CoA dehydrogenase (VLCAD) deficiency, carnitine palmitoyl transferase (CPT I OR CPT II) deficiency, long-chain 3-hydroxy-acyl-CoA dehydrogenase (LCHAD) deficiency, trifunctional protein (TFP) deficiency, or carnitine-acylcarnitine translocase (CACT) deficiency. The use of any other medium-chain-triglyceride (MCT) product should be discontinued before starting Dojolvi. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# doptelet

---

## Products Affected

- DOPTelet (10 TAB PACK)
- DOPTelet (15 TAB PACK)
- DOPTelet (30 TAB PACK)

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis. While no specific lab/diagnostic tests required, providing the results used to diagnose the condition is recommended, thereby reducing the likelihood that additional information will be needed to process the request. |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a hematologist, gastroenterologist, hepatologist, or surgeon.   |
| <b>Coverage Duration</b>            | One month for chronic liver disease-associated thrombocytopenia. Two years for chronic ITP.   |
| <b>Other Criteria</b>               | UNDER CMS REVIEW  |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# doxepin topical cream

---

## Products Affected

- *doxepin topical*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Doxepin topical cream will be covered for the treatment of short-term management of moderate pruritus in adults with atopic dermatitis or lichen simplex chronicus. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# dronabinol

---

## Products Affected

- *dronabinol*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | Anorexia due to AIDS - 1 yr. Chemo-induced nausea/vomiting-6 mos. Post-op nausea/vomiting-1 month.   |
| <b>Other Criteria</b>               | For the prophylaxis of nausea and vomiting associated with cancer chemotherapy or for the prophylaxis of post-operative nausea and vomiting, there must be a documented failure of one 5HT-3 receptor antagonist. There are no additional requirements for patients with AIDS-associated loss of appetite. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |



# droxidopa

---

## Products Affected

- *droxidopa*

| <b>PA Criteria</b>                  | <b>Criteria Details</b>   |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# dupixent

## Products Affected

- DUPIXENT SUBCUTANEOUS PEN INJECTOR  
200 MG/1.14 ML, 300 MG/2 ML
- DUPIXENT SUBCUTANEOUS SYRINGE 100  
MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis. For MODERATE-TO-SEVERE EOSINOPHILIC ASTHMA: (1) either a) submission of blood eosinophil count of at least 150 cells/mcL obtained within 6 weeks of therapy initiation or b) documentation asthma requires daily oral corticosteroid for control and (2) adult pts with pre-bronchodilator FEV1 less than 80% predicted and (3) experienced inadequate control of asthma sxs or severe intolerance with both Fasenra and Nucala. For MODERATE TO SEVERE ATOPIC DERMATITIS: documentation of a trial of 2 of the following 3 options during the 6 mos preceding request: a) tx w/ high-potency topical steroid for minimum 14-day duration or tx w/ a medium-potency topical steroid for a min. 28-day duration, b) tx w/ topical tacrolimus, c) tx w/ an oral or injectable immunosuppressant, such as a corticosteroid indicated or compendia supported for tx of AD. For CHRONIC RHINOSINUSITIS WITH NASAL POLYPS: (1) documentation of inadequate response to 3-month trial of Xhance nasal spray and inadequate response with Nucala and (2) trial with oral steroids in past 6 months or prior sinus surgery in past 2 years. For EOSINOPHILIC ESOPHAGITIS: (1) diagnosis confirmed by upper endoscopy w/ biopsy and (2) clinical sxs such as difficulty swallowing, food impaction (getting stuck in the esophagus), acid reflux, n/v, abdominal or chest pain), and (3) provider must attest that other causes have been ruled out (including, but not limited to: GERD, HES, EGPA) and (4) documentation of serious side effects or drug failure with the following compendia-supported standard of care treatments: topical steroids (such as swallowed fluticasone or budesonide) with a PPI at twice daily dosing for at least 8 wks. For PRURIGO NODULARIS: (1) pruritis lasting at least 6 weeks (2) signs of repeated scratching, picking, or rubbing (i.e., excoriations and scars), (3) presence of multiple pruriginous firm, nodular lesions and (4) a history of failing at least a 2-week course of high-to-super-high-potency topical steroid. |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an allergist, gastroenterologist, immunologist, otolaryngologist, pulmonologist or dermatologist   |
| <b>Coverage Duration</b>            | Atopic dermatitis: 1 yr. All other diagnoses: initial - 6 months, recert every 1 year thereafter   |

| PA Criteria                | Criteria Details   |
|----------------------------|--|
| <b>Other Criteria</b>      | <p>For ASTHMA: Dupixent must be used as add-on tx to existing maintenance tx. For ATOPIC DERMATITIS: must involve at least 10% body surface area prior to initial therapy. For CHRONIC RHINOSINUSITIS WITH NASAL POLYPS: recertification will require documentation of continued use of intranasal corticosteroid and clinical benefit from Dupixent use (e.g., reduced polyp size, improved nasal congestion, reduced sinus opacification, decreased sino-nasal sxs, improved sense of smell). For EOSINOPHILIC ESOPHAGITIS: the diagnosis confirmed by upper endoscopy w/ esophageal biopsy must show at least 15 eosinophils per high-power field (or 60 eos/mm<sup>2</sup>). A positive response may include symptom resolution (an improvement in swallowing, decreased reflux, decreased food impaction) or other subjective or objective evidence from provider that use of Dupixent has improved the patient's condition. For PRURIGO NODULARIS: recertification requires a reduction in symptoms (pruritis) and clearer skin (less firm nodular lesions) from baseline/initial request. RECERTIFICATION for all indications requires some objective or subjective evidence of a positive response to treatment. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements.</p> |
| <b>Indications</b>         | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>      |  |
| <b>Part B Prerequisite</b> | No   |

# enbrel

---

## Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS RECON SOLN
- ENBREL SUBCUTANEOUS SOLUTION
- ENBREL SUBCUTANEOUS SYRINGE
- ENBREL SURECLICK

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis. |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.            |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an appropriate specialist to treat the stated diagnosis.            |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | UNDER CMS REVIEW  |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# endari

---

## Products Affected

- *glutamine (sickle cell)*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a hematologist  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for symptomatic pain relief of sickle cell disease. In addition, patient must have experienced inadequate pain relief with a minimum three-month trial or a hematologic toxicity reaction with hydroxyurea monotherapy. Hematologic toxicity with hydroxyurea is defined by neutrophil, platelet, hemoglobin and/or reticulocyte count abnormalities concurrent with hydroxyurea. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# enspryng

---

## Products Affected

- ENSPRYNG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis of neuromyelitis optica spectrum disorder (NMOSD) confirmed by a positive anti-aquaporin-4 (AQP4) antibody test (results must be provided).  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an ophthalmologist or neurologist.   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of Neuromyelitis Optica spectrum disorder (NMOSD) confirmed by a positive anti-aquaporin-4 (AQP4) antibody test. Patient must have had at least 2 Neuromyelitis Optica relapses in the last 24 months, one of which being within the last 12 months. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# epidiolex

---

## Products Affected

- EPIDIOLEX

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# erleada

---

## Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an oncologist or hematologist.  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for a diagnosis of nonmetastatic, castration-resistant prostate cancer in patients with documentation of contraindication or had serious side effects to Nubeqa and Xtandi. Covered for a diagnosis of metastatic castration-sensitive prostate cancer in patients with documentation of contraindication or serious side effects to abiraterone and either Xtandi or Nubeqa. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |



# esrd

---

## Products Affected

- PROCRT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML
- RETACRIT

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, dialysis status (only if diagnosis of end-stage renal disease)   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | For a diagnosis of end stage renal disease on dialysis, CMS expects that this drug should routinely be provided by a dialysis center and billed to Medicare Part B as part of a bundled payment arrangement (if applicable). All other diagnoses unrelated to end stage renal disease on dialysis would be evaluated for coverage under the Part D benefit. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# evenity

## Products Affected

- EVENITY

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, DEXA scan report(s), previous therapies  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year (refer to other criteria section)  |
| <b>Other Criteria</b>               | Covered for post-menopausal women at high risk for fracture. The patient must be considered high risk for fracture, which is defined as 1) history of previous osteoporosis-related fracture, 2) T- score of -2.5 SD or less, 3) T-score between -1.0 and -2.5 SD below normal and a FRAX score for hip fracture of 3% or greater or the risk for other bone fracture is 20% or greater. Patient must also have experienced therapeutic failure, severe intolerance or a contraindication to an oral bisphosphonate or be an inappropriate candidate for oral bisphosphonate therapy based on clinical presentation. Therapeutic failure is defined as a decrease in bone mineral density or a fracture while on bisphosphonate therapy. Severe intolerance defined as chest pain, difficulty swallowing, intense abdominal pain or chronic dyspepsia when oral bisphosphonate therapy was taken according to manufacturer recommendations. Oral bisphosphonates may be clinically inappropriate for a patient that is bedridden/unable to sit upright for 30 minutes unsupervised or has esophageal ulcerations, esophageal stricture, Barrett's Esophagitis, or active ulcers. Additionally, patient must have documented severe intolerance or contraindication to generic teriparatide. The FDA approved labeling does not recommend duration to exceed more than 12 monthly doses. Request will also be evaluated for part b versus part d coverage. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# evrySDI

## Products Affected

- EVRYSDI

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, including supporting labs/diagnostic test results.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by or in consultation with a provider who specializes in the treatment of Spinal Muscular Atrophy (SMA) and/or neuromuscular disorders   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of Type I, II, or III Spinal Muscular Atrophy confirmed by targeted mutation analysis showing homozygous deletions of SMN1 gene or homozygous mutation in the SMN1 gene (e.g., biallelic mutations of exon 7) or compound heterozygous mutation in the SMN1 gene (e.g., deletion of SMN1 exon 7 and mutation of SMN1). Patient must have genetic testing confirming 1, 2, 3, or 4 copies of the SMN2 gene. Additionally, progress notes containing results of at least one of the following baseline motor function exams must be provided: a) Hammersmith Infant Neurological exam (HINE) or b) Hammersmith Functional Motor Scale Expanded (HFMSE) or c) Upper Limb Module (ULM) test/Revised Upper Limb Module test (RULM) or d) Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) or e) Motor Function Measure 32 (MFM32) or f) Bayley Scales of Infant and Toddler Development- Third Edition gross motor scale (BSID-III) (for infantile-onset disease only). Recertification will require documentation of objective improvement of motor function relative to baseline as measured by retest of pretreatment exam. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# fasenra

## Products Affected

- FASENRA PEN
- FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling and Fasenra will not be covered for the treatment of other eosinophilic conditions or for relief of acute bronchospasm or status asthmaticus.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent lab/diagnostic test results to confirm the diagnosis of eosinophilic asthma (such as blood eosinophil count, pulmonary function tests, or other tests performed to confirm the diagnosis), and documentation of previous therapies   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an allergist, immunologist, or pulmonologist  |
| <b>Coverage Duration</b>            | Initial approval - 6 months. Recertifications - 1 year.   |
| <b>Other Criteria</b>               | Covered for the treatment of severe persistent asthma with an eosinophilic phenotype. For a patient not dependent on oral steroids, the patient must have a peripheral blood eosinophil count of at least 300 cells per microliter within the preceding 6 weeks before the Fasenra request. For a patient dependent on oral steroids, the patient must have a peripheral blood eosinophil count of at least 150 cells per microliter within the preceding 6 weeks before Fasenra request. For adults, patient must have a pre-bronchodilator forced expiratory volume in 1 second (FEV1) of less than 80% of the predicted value. For patients ages 12-18 years, patient must have a pre-bronchodilator FEV1 of less than 90% of the predicted value or a ratio of the FEV1 to the forced vital capacity (FVC) of less than 0.8. The patient must be maintained on asthma treatment consistent with the GINA or NHLBI guidelines, which recommend the combination of a high-dose inhaled steroid with a long-acting beta agonist (preferred by GINA guidelines), or leukotriene inhibitor, or long-acting muscarinic antagonist, or theophylline. If the above criteria are met, coverage will be provided if the patient experienced 2 or more asthma exacerbations (defined as unscheduled doctor visits, urgent care visits, emergency room visits, hospital admissions, or documented need for acute systemic steroids) within the preceding 12 months. Initial approval will be for 6 months. Upon recertification, documentation should be provided validating reduction in asthma exacerbations as defined above. Requests will also be evaluated for part B vs part D coverage. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |

| <b>PA Criteria</b>         | <b>Criteria Details</b>             |
|----------------------------|-------------------------------------|
| <b>Indications</b>         | All Medically-accepted Indications. |
| <b>Off Label Uses</b>      |                                     |
| <b>Part B Prerequisite</b> | No                                  |

# filspari

## Products Affected

- FILSPARI ORAL TABLET 200 MG, 400 MG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a nephrologist or provider specializing in IgA nephropathy.  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered to reduce proteinuria in patients with a diagnosis of primary immunoglobulin A nephropathy (IgAN), confirmed on biopsy. Patient must have an eGFR greater than 35mL/min/1.73m <sup>2</sup> and have proteinuria (defined as greater than or equal to 1 g/day OR a urine protein creatinine ratio (UPCR) greater than or equal to 1.5 g/g). In addition, the patient must have received the maximally tolerated dose of an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) for a minimum of 3 months prior to starting Filspari, unless the patient is unable to tolerate or has a contraindication to an ACEi or ARB. Recertification will require documentation of an eGFR of at least 30 mL/min/1.73 m <sup>2</sup> AND either a reduction in total urine protein from baseline OR a reduction in UPCR from baseline. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# fintepla

---

## Products Affected

- FINTEPLA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# firdapse

---

## Products Affected

- FIRDAPSE

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, pertinent lab/diagnostic test results  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist or neuromuscular specialist   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of Lambert-Eaton Myasthenic Syndrome that has been confirmed by electromyography or calcium channel antibody testing. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |



# **gabapentin ER**

---

## **Products Affected**

- *gabapentin oral 24-h er tab 300 mg, 600 mg*

| <b>PA Criteria</b>                  | <b>Criteria Details</b>  |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | For the treatment of post-herpetic neuralgia, there must be documentation of severe intolerance or clinical failure to generic immediate release gabapentin. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# **gattex**

---

## **Products Affected**

- GATTEX 30-VIAL

| <b>PA Criteria</b>                  | <b>Criteria Details</b>   |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis and evidence of dependency on parenteral nutrition support.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | 6 months  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# GLP-1 Agonists

---

## Products Affected

- OZEMPIC
- RYBELSUS
- TRULICITY

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Excluded for weight management and as limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for the treatment of type 2 diabetes mellitus. Excluded for use in weight management. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# gonadotropin releasing hormone analogs

## Products Affected

- ELIGARD
- ELIGARD (3 MONTH)
- ELIGARD (4 MONTH)
- ELIGARD (6 MONTH)
- *leuprolide (3 month)*
- *leuprolide subcutaneous kit*
- LUPRON DEPOT
- LUPRON DEPOT (3 MONTH)
- LUPRON DEPOT (4 MONTH)
- LUPRON DEPOT (6 MONTH)
- LUPRON DEPOT-PED (3 MONTH)
- INTRAMUSCULAR SYRINGE KIT 11.25 MG, 30 MG
- LUPRON DEPOT-PED INTRAMUSCULAR KIT 11.25 MG, 15 MG, 7.5 MG (PED)
- LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT
- TRELSTAR INTRAMUSCULAR RECON SUSP

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | 6 months for endometriosis. One year for all other diagnoses.   |
| <b>Other Criteria</b>               | Lupron/leuprolide is covered for management of endometriosis, including pain relief and reduction of endometriotic lesions. Authorization will be for up to 6 months, because of a lack of safety data with long term use and concerns regarding effects on bone density. Lupron/leuprolide is covered for treatment of advanced prostate cancer, defined as stage III or stage IV. Lupron/leuprolide is covered for treatment of precocious puberty. Lupron/leuprolide is covered as adjunct therapy for preoperative hematologic improvements of patients with anemia (hematocrit less than or equal to 30% and or hemoglobin less than or equal to 10.2 g/dL) caused by uterine leiomyomata. Trelstar is covered for treatment of advanced prostate cancer. Requests will also be evaluated for off-label use. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# growth hormone

## Products Affected

- OMNITROPE

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | When used to increase height, growth hormone therapy will not be covered in pediatric patients with closed epiphyses.  |
| <b>Required Medical Information</b> | General-growth charts, height/weight, height velocity. Somatotropin deficiency in children requires documentation of diminished growth hormone response (max peak less than 10ng/mL) to 2 or more different provocation tests (such as levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon) or documentation of low IGF-1 or IGFBP3 for age, sex, and pubertal status in children age 6 or greater in the absence of chronic disease along with a height velocity less than 25th percentile in the 6-12 months prior to growth hormone therapy. In addition to one of the above findings there must also be documentation of two of the following: 1) growth velocity less than 7cm/yr before age three 2) bone age at least 2 SD below normal for chronological age 3) a known risk factor for growth hormone deficiency (such as congenital hypopituitarism, panhypopituitarism, or prior brain radiation). Somatotropin deficiency in adults requires documentation of negative response to provocative test with max peak of 5ng/mL along with documentation of clinical symptoms such as increased weight and body fat mass, decreased lean body mass, decreased exercise tolerance, decreased muscle mass and strength, reduced cardiac performance, reduced bone density, poor sleep, impaired sense of well-being or lack of motivation. Alternatively, will accept insulin tolerance test with max peak less than 5ng/mL (unless contraindicated in which case will accept IV arginine in combination with GH-releasing hormone with max peak less than 10ng/mL.) If there is documentation of deficiency of 3 or more pituitary hormones, ITT or arginine tests are not required. Recertification- in children requires the following every 12 months: current growth velocity, growth charts (height and weight), current bone age, puberty status, and radiographic testing to determine if epiphyses are closed at age 14 in girls and age 16 in boys. |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an endocrinologist, pediatric endocrinologist, nephrologist, infectious disease specialist, or gastroenterologist.   |
| <b>Coverage Duration</b>            | One year   |

| PA Criteria                | Criteria Details   |
|----------------------------|--|
| <b>Other Criteria</b>      | <p>Children-covered for treatment of short stature in Turner Syndrome. Covered for children with height less than 3rd percentile for chronological age with renal insufficiency defined as serum creatinine greater than 3.0 mg/dL or creatinine clearance of 5-75 mL/min per 1.73m<sup>3</sup> before renal transplant. Covered for Prader-Willi syndrome with short stature or growth failure. Covered for children with intrauterine growth failure or small for gestational age who do not catch up by 2 years of age. Covered for Noonan Syndrome with short stature (when height is at least 2 SD below normal. Covered for children with SHOX deficiency demonstrated by chromosome analysis and whose epiphyses are not closed. Adults and children- growth hormone therapy is covered for a diagnosis of somatotropin deficiency (see required medical info). Covered for AIDS wasting or cachexia or children with HIV associated failure to thrive defined as a greater than 10% of baseline weight loss or weight less than 90% of ideal body weight and either chronic diarrhea or chronic weakness not otherwise explained. Covered for patients with short bowel syndrome who are experiencing malabsorption, malnutrition, weight loss or dehydration despite specialized nutritional support.</p> |
| <b>Indications</b>         | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>      |  |
| <b>Part B Prerequisite</b> | No   |

# hadlima

---

## Products Affected

- HADLIMA
- HADLIMA (CITRATE-FREE)
- HADLIMA (CITRATE-FREE) PUSHTOUCH
- HADLIMA PUSHTOUCH

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis. |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.            |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an appropriate specialist to treat the stated diagnosis.            |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | UNDER CMS REVIEW  |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# humira

## Products Affected

- HUMIRA PEN (ABBVIE NDCS STARTING WITH 00074- ONLY)
- HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML (ABBVIE NDCS STARTING WITH 00074- ONLY)
- HUMIRA(CF) PEN CROHNS-UC-HS (ABBVIE NDCS STARTING WITH 00074- ONLY)
- HUMIRA(CF) PEN PEDIATRIC UC (ABBVIE NDCS STARTING WITH 00074- ONLY)
- HUMIRA(CF) PEN PSOR-UV-ADOL HS (ABBVIE NDCS STARTING WITH 00074- ONLY)
- HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 80 MG/0.8 ML
- HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | UNDER CMS REVIEW   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an appropriate specialist to treat the stated diagnosis.   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | For ANKYLOSING SPONDYLITIS (AS), CROHN'S DISEASE, HIDRADENITIS SUPPURATIVA, JUVENILE IDIOPATHIC ARTHRITIS (JIA), PLAQUE PSORIASIS, PSORIATIC ARTHRITIS (PsA), RHEUMATOID ARTHRITIS (RA), ULCERATIVE COLITIS (UC), POSTERIOR UVEITIS AND PANUVEITIS, contraindication or inability to use both formulary adalimumab biosimilars, Hadlima and Simlandi, is required. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |



# hyftor

---

## Products Affected

- HYFTOR

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, including supporting labs/diagnostic test results.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a dermatologist, neurologist, or geneticist.  |
| <b>Coverage Duration</b>            | Initial 3 months. Recertifications 6 months.  |
| <b>Other Criteria</b>               | Covered for treatment of facial angiofibroma associated with tuberous sclerosis. Patient must have three or more angiofibroma papules at baseline (each at least 2 mm in diameter and with redness) on the face. Initial recertification requires provider documentation of objective and/or subjective evidence of reduced angiofibroma size and/or redness resulting from use of Hyftor. Subsequent recertifications require providers objective and/or subjective evidence that use of Hyftor has provided patient with continued stability or further improvement from status noted at initial recertification. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# increlex

---

## Products Affected

- INCRELEX

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Increlex will not be covered for growth promotion in patients with closed epiphyses or as a substitute for growth hormone replacement therapy. IV administration will not be covered.   |
| <b>Required Medical Information</b> | Diagnosis, including supporting labs/diagnostic test results (such as IGF-1 levels and GH levels).  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an endocrinologist, pediatric endocrinologist, or nephrologist.   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Increlex will be covered in patients with severe primary IGF-1 deficiency defined as height SD score less than -3.0, basal IGF-1 SD score less than -3.0, and normal or elevated GH. They will also be covered in patients with growth hormone (GH) gene deletion with the development of neutralizing antibodies to GH. Normal dose is 40-120mcg/kg sq twice daily given 20 minutes before or after a meal or snack to avoid hypoglycemia. Doses greater than 120mcg/kg will not be covered. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# ingrezza

---

## Products Affected

- INGREZZA INITIATION PACK
- INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG
- INGREZZA SPRINKLE ORAL SPRINKLE CAP 40 MG, 60 MG, 80 MG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist or a psychiatrist   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# INJECTABLE ONCOLOGY

---

## Products Affected

- ELREXFIO
- PHESGO

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | DIAGNOSIS, CURRENT AND PREVIOUS THERAPIES FOR STATED DIAGNOSIS (IF APPLICABLE). WHILE NO SPECIFIC LAB/DIAGNOSTIC TESTS REQUIRED, PROVIDING THE RESULTS USED TO DIAGNOSE THE CONDITION IS RECOMMENDED, THEREBY REDUCING THE LIKELIHOOD THAT ADDITIONAL INFORMATION WILL BE NEEDED TO PROCESS THE REQUEST. |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | MUST BE PRESCRIBED BY AN ONCOLOGIST OR HEMATOLOGIST  |
| <b>Coverage Duration</b>            | ONE YEAR   |
| <b>Other Criteria</b>               | REQUESTS FOR NON-FDA APPROVED INDICATIONS WILL BE EVALUATED ACCORDING TO THE MEDICARE STATUTORY OFF-LABEL USE REQUIREMENTS.  |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# isturisa

## Products Affected

- ISTURISA ORAL TABLET 1 MG, 5 MG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling and excluded for other forms of Cushing's Syndrome not Cushing's disease.   |
| <b>Required Medical Information</b> | Diagnosis, mean urinary free cortisol (UFC) level measured over three 24-hour, current and previous therapies used for the treatment of the stated diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an endocrinologist.  |
| <b>Coverage Duration</b>            | Initial approval and increase in dose 3 months. Recertification of previously approved dose 1 year.  |
| <b>Other Criteria</b>               | Covered for a diagnosis of Cushing's disease in patients with documentation of clinical symptoms (such as diabetes, central obesity, moon face, buffalo hump, osteoporosis, muscle wasting, hypertension, depression, or anxiety) who have a mean urinary free cortisol (UFC) level that is at least 1.5x the upper limit of normal measured over three 24-hour measurements (ULN = 50 mcg/24 hours or 145 nmol/24 hours). Also, there must be documentation of a failed pituitary surgery or contraindication to pituitary surgery as well as serious side effects or drug failure with Signifor/pasireotide. A dose increase request will require both documentation to show UFC levels above the upper limit of normal on current dose and documentation that the patient is still experiencing Cushing's disease symptoms. All dose increases approved for 3 months. Recertification of the same dose will require both documentation of a recent UFC level within normal limits and documentation of improvement in the symptoms of Cushing's disease. Recertifications at same dose as previously approved are approved for 1 year. For all requests, the prescriber must make clear the dose they are planning to use. Recertification at a previously approved dose (maintenance dosing) will allow the dose requested only. Dose increases must be in accordance with FDA labeling and titrated by no greater than 1 mg or 2 mg twice daily, no more frequently than every 2 weeks based on the rate of cortisol changes, individual tolerability, and improvement in signs and symptoms. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |

| <b>PA Criteria</b>             | <b>Criteria Details</b> |
|--------------------------------|-------------------------|
| <b>Part B<br/>Prerequisite</b> | No                      |

# ivig

## Products Affected

- GAMMAGARD LIQUID
- GAMMAKED
- GAMUNEX-C
- OCTAGAM
- PRIVIGEN

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Excluded under Part D if intravenous immune globulin (IVIG) is provided in the home for individual with diagnosis of primary immune deficiency disease.                               |
| <b>Required Medical Information</b> | UNDER CMS REVIEW  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | Two years for chronic conditions. One month for acute conditions. 5 days for Guillain-Barre   |
| <b>Other Criteria</b>               | Requests will be evaluated for Part B vs Part D coverage. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# joenja

## Products Affected

- JOENJA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an immunologist, allergist, hematologist, or provider who specializes in the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)   |
| <b>Coverage Duration</b>            | Initial approval - 6 months. Recertifications - 1 year.   |
| <b>Other Criteria</b>               | Covered for a diagnosis of activated phosphoinositide 3-kinase (PI3K) delta syndrome (APDS) in patients 12 years of age or older and who weigh at least 45 kg. Must have a confirmed APDS-associated genetic PI3K-delta mutation with a documented variant in either PIK3CD or PIK3R1 AND must meet at least one of the following: a. Have nodal and/or extranodal lymphoproliferation OR b. Have presence of at least 1 measurable nodal lesion on CT or MRI OR c. Have clinical findings and manifestations compatible with APDS (such as history of repeated oto-sino-pulmonary infections, organ dysfunction (i.e., lung, liver), bronchiectasis, cytopenias, gastrointestinal disease, immune dysregulation (i.e., decreased naive B cells, reversed CD4/CD8 ratio)). ?Recertification will require documentation that the patient has responded to therapy (i.e., improvement in clinical findings and/or manifestations of APDS such lymphoproliferation, recurrent infections, cytopenia, immunophenotyping) OR subjective evidence from provider that Joenja has improved patient's condition. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |



# juxtapid

## Products Affected

- JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling  |
| <b>Required Medical Information</b> | Diagnosis, lab/diagnostic test results (must include baseline LDL level), current and previous therapies for stated diagnosis.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a Cardiologist, Endocrinologist, or Lipidologist  |
| <b>Coverage Duration</b>            | Initial approval - 26 weeks. Recertifications - 1 year.   |
| <b>Other Criteria</b>               | Clinical diagnosis will be based on inclusion criteria for clinical trial: documented functional mutation in both LDL receptor alleles or skin fibroblast LDL receptor activity less than 20% of normal, or untreated total cholesterol more than 500 mg/dL and triglycerides less than 300 mg/dL and both parents with documented total cholesterol more than 250 mg/dL. Baseline LDL must be greater than 130 despite use of the following combination of moderate dose (atorvastatin 40 or equivalent) high-potency statin (atorvastatin, rosuvastatin, pitavastatin, simvastatin) with another lipid lowering agent. For patients with a contraindication or intolerance to statin therapy, the use of other lipid lowering agents will meet this prerequisite requirement. Documentation of lack of response or severe intolerance to Repatha is required. Initial approval will be 26 weeks. Further approval will require evidence of improvement over baseline LDL level. If LDL level meets recertification requirements, then the request will be reviewed annually thereafter. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# jynarque

## Products Affected

- JYNARQUE ORAL TABLET 15 MG, 30 MG
- JYNARQUE ORAL SEQUENTIAL TAB

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis. While no specific lab/diagnostic tests required, providing the results used to diagnose the condition is recommended, thereby reducing the likelihood that additional information will be needed to process the request.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a nephrologist   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for the diagnosis of autosomal dominant polycystic kidney disease (ADPKD). ADPKD must be rapidly progressing, as defined by either 1) confirmed GFR decline of at least 5 ml/min/1.73 m <sup>2</sup> per year over 1 year and/or 2.5 ml/min/1.73 m <sup>2</sup> per year over a period of 5 years or 2) total kidney volume increase of at least 5% per year confirmed by repeated ultrasound or MRI measurements taken at least 6 months apart. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# kalydeco

---

## Products Affected

- KALYDECO

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | COVERAGE WILL BE EXCLUDED IN PATIENTS WITH CYSTIC FIBROSIS WHO ARE HOMOZYGOUS FOR THE F508 DEL MUTATION IN THE CFTR GENE.   |
| <b>Required Medical Information</b> | Diagnosis, lab/diagnostic results to include testing for CFTR gene mutation that is responsive to ivacaftor                 |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# kerendia

---

## Products Affected

- KERENDIA

| <b>PA Criteria</b>                  | <b>Criteria Details</b>  |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, previous therapies for requested condition.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by or in consultation with a nephrologist or endocrinologist.   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for chronic kidney disease associated with type 2 diabetes in patients with inadequate response to ACE-I or ARB, AND an SGLT2. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# keveyis

---

## Products Affected

- *dichlorphenamide*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist or geneticist.  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# kevzara

---

## Products Affected

- KEVZARA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a rheumatologist   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for the diagnosis of moderate to severe rheumatoid arthritis in patients with documented failure to two of the following alternatives: Enbrel, Hadlima, Orencia, Rinvoq, Xeljanz/XR. Covered for the diagnosis of polymyalgia rheumatica (PMR) in patients who have had an inadequate response to corticosteroids or who cannot tolerate a corticosteroid taper. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# lidocaine patch

---

## Products Affected

- *lidocaine topical patch 5 %*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# livmarli

---

## Products Affected

- LIVMARLI ORAL SOLUTION 9.5 MG/ML

| <b>PA Criteria</b>                  | <b>Criteria Details</b>  |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | UNDER CMS REVIEW   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis. |
| <b>Prescriber Restrictions</b>      | UNDER CMS REVIEW   |
| <b>Coverage Duration</b>            | Initial approval - 6 months. Recertifications - 1 year.                        |
| <b>Other Criteria</b>               | UNDER CMS REVIEW   |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |



# Lupkynis

## Products Affected

- LUPKYNIS

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, kidney biopsy results, baseline urine protein/creatinine ratio (UPCR) at time of request, baseline eGFR at time of request, current and previous therapies used for the treatment of the stated diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a rheumatologist or nephrologist   |
| <b>Coverage Duration</b>            | Initial approval - 6 months. Recertifications - 1 year.  |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of class III, IV, or V lupus nephritis (LN) confirmed by kidney biopsy. Patient must be established and continue on standard therapy with mycophenolate/MMF and corticosteroids. Lupkynis is not approved for use as monotherapy or with cyclophosphamide-based immunosuppressive therapy. Also, patient must have had previous trial and failure or severe intolerance with Benlysta/belimumab, used either for systemic lupus erythematosus (SLE) or LN. Recertification after initial 6-month approval requires reduction in UPCR from baseline and increase in eGFR from baseline. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# mavyret

---

## Products Affected

- MAVYRET ORAL PELLETS IN PACKET
- MAVYRET ORAL TABLET

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Mavyret will not be covered in patients with moderate or severe hepatic impairment (Child-Pugh B or C). Mavyret will not be covered for genotypes that are not supported by its FDA approved indication, compendia, or AASLD guidelines. |
| <b>Required Medical Information</b> | Diagnosis, pertinent lab/diagnostic test results including baseline HCV RNA results and HCV genotype, and documentation of current and previous therapies (if applicable).   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a gastroenterologist, hepatologist, infectious disease specialist, or HCV/HIV specialist   |
| <b>Coverage Duration</b>            | 8 to 16 weeks (depending on diagnosis, FDA approved labeling, and AASLD/IDSA guidance)   |
| <b>Other Criteria</b>               | For off-label Mavyret reviews, criteria will be applied consistent with compendia and current AASLD/IDSA guidance.   |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# metformin ER

---

## Products Affected

- *metformin oral 24-h er tab*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for the diagnosis of Type-2 diabetes. Documentation of clinical failure or severe intolerance of both immediate-release metformin (generic equivalent of Glucophage) and extended-release metformin (generic equivalent of Glucophage XR) is required before the approval of metformin ER osmotic (generic Fortamet). Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# methamphetamine

---

## Products Affected

- *methamphetamine*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Excluded when used for weight loss, even if non-cosmetic (such as morbid obesity).  |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# mifepristone

## Products Affected

- *mifepristone oral tablet 300 mg*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Excluded in patients who are pregnant, who have a history of unexplained vaginal bleeding/endometrial changes, who are currently receiving long-term corticosteroids, or who are currently on simvastatin, lovastatin or a medication that is a CYP3a substrate and has a narrow therapeutic range.   |
| <b>Required Medical Information</b> | Documentation of diagnosis, pertinent lab/diagnostic test results (such as HbA1c levels and negative pregnancy test in women of childbearing age), and documentation of previous therapies (failure of surgery or not a candidate for surgery).   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an endocrinologist.   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered in patients with a diagnosis of endogenous Cushing's syndrome and Type 2 diabetes or glucose intolerance. Patients must have failed surgery or not be a candidate for surgery. Women of childbearing age must have a negative pregnancy test prior to starting therapy and must not be nursing. Non-hormonal contraception must be used while on therapy, unless the patient has had a surgical sterilization, in which case, no additional contraception is needed. Hypokalemia should be corrected prior to treatment and monitored for during treatment. Patients should also be closely monitored for signs and symptoms of adrenal insufficiency. Recertification after one year will require the submission of patient progress notes and lab work that demonstrates clinical response or stabilization of disease. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# miglustat

---

## Products Affected

- *miglustat*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Combination therapy of miglustat (Zavesca) and Cerezyme/Ceredase is excluded.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent lab/diagnostic test results (such as enzyme analysis, mutation analysis, bone marrow studies, or other tests performed to confirm the diagnosis)                              |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Miglustat is covered for Type 1 Gaucher Disease in patients for whom enzyme replacement therapy with Cerezyme is not a therapeutic option due to allergy, hypersensitivity, or poor venous access. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# migraine other

---

## Products Affected

- NURTEC ODT

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a headache or pain specialist or neurologist  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | For the acute treatment of migraine headache with or without aura, Nurtec is covered with documentation of trial and failure or severe intolerance to one generic triptan product. For the prevention of episodic migraine, Nurtec requires previous trials with two different classes of medications, for at least eight weeks per trial, that are supported by compendia for the prophylactic treatment of migraine headache (such as amitriptyline, divalproex sodium, propranolol, topiramate, or venlafaxine) which resulted in intolerance or lack of clinical efficacy. For clinical failure due to intolerance, an eight-week trial of medication is not required. Recertification after initial approval will require documentation that the drug continues to effectively reduce frequency, duration, and severity of acute migraine headaches for the patient. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# motpoly xr

---

## Products Affected

- MOTPOLY XR ORAL 24-H ER CAP 100 MG, 150 MG, 200 MG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.           |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | UNDER CMS REVIEW   |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |



# myalept

---

## Products Affected

- MYALEPT

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Use of Myalept is excluded for the following conditions: metabolic disease not associated with congenital leptin deficiency, HIV-associated lipodystrophy   |
| <b>Required Medical Information</b> | Diagnosis, including supporting labs/diagnostic test results.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for the treatment of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Diagnosis is confirmed through low serum leptin levels and the absence of subcutaneous fat. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# mytesi

---

## Products Affected

- MYTESI

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Drug therapy will not be authorized for individuals who have a history of Ulcerative colitis, Crohn's disease, Celiac sprue, chronic pancreatitis, malabsorption, or any other GI disease associated with diarrhea.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for the symptomatic relief of noninfectious diarrhea in individuals with HIV/AIDS on anti-retroviral therapy. In addition, documentation of clinical failure to either loperamide or diphenoxylate is required. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# namzarin

---

## Products Affected

- NAMZARIC ORAL 24-H ER SPRINKLE CAP DOSE PACK
- NAMZARIC ORAL 24-H ER SPRINKLE CAP

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Namzarin will be authorized for patients with a diagnosis of moderate to severe Alzheimer disease. There must also be documented stabilization on donepezil for a minimum of three months immediately preceding the request for Namzarin. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# nitisinone

## Products Affected

- *nitisinone*
- NITYR

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, current therapies, pertinent lab/diagnostic test results  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by or in consultation with a physician specializing in the treatment of Tyrosinemia type 1 (such as a metabolic disease specialist).  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of hereditary tyrosinemia type 1. Patients must have the presence of succinylacetone (SSA) in the urine or blood / dried blood spots. Patients must have clinical features of tyrosinemia type 1, such as: failure to thrive, emesis, melena, hepatosplenomegaly, liver disease, cirrhosis, clotting abnormalities, renal disease/Fanconi syndrome, neurological crisis, rickets. Requests for Nityr tablets require documentation of severe intolerance or drug failure of the preferred product generic nitisinone capsules. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# nucala

## Products Affected

- NUCALA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Nucala will not be covered for the relief of acute bronchospasm or status asthmaticus. Nucala will not be approved for granulomatosis with polyangiitis (also known as GPA or Wegeners granulomatosis) or microscopic polyangiitis.                         |
| <b>Required Medical Information</b> | Diagnosis, pertinent lab/diagnostic tests used to confirm diagnosis, current and previous therapies. For diagnosis of EGPA, baseline Birmingham vasculitis activity score (BVAS) from within 4 weeks prior to start of Nucala therapy must also be provided |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | For asthma with eosinophilic phenotype, must be prescribed by an Allergist, Immunologist or Pulmonologist. For EGPA, must be prescribed by an Allergist, Immunologist, Pulmonologist, Neurologist, or Rheumatologist.                                       |
| <b>Coverage Duration</b>            | Initial approval - 6 months. Recertifications - 1 year.   |
| <b>Other Criteria</b>               | UNDER CMS REVIEW  |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# nuedexta

---

## Products Affected

- NUEDEXTA

| <b>PA Criteria</b>                  | <b>Criteria Details</b>  |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis. |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Requests will also be evaluated for off-label use.                             |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# nuplazid

---

## Products Affected

- NUPLAZID

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Per the black box warning on Nuplazid, elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Therefore, Nuplazid will not be covered for elderly patients with dementia-related psychosis. |
| <b>Required Medical Information</b> | Diagnosis, including supporting labs/diagnostic test results.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist, psychiatrist, or geriatrician  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements.   |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# ocaliva

## Products Affected

- OCALIVA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Patients with complete biliary obstruction will be excluded from coverage.   |
| <b>Required Medical Information</b> | Diagnosis, documentation of current and previous therapies for stated diagnosis, pertinent lab results (such as ALP levels, bilirubin, antimichondrial antibody/AMA test)  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a gastroenterologist or hepatologist   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Ocaliva will be covered for the diagnosis of primary biliary cholangitis that has been confirmed by 2 of the following: positive antimitochondrial antibodies (AMA), history of increased alkaline phosphatase (ALP) levels, or liver biopsy consistent with primary biliary cholangitis. In addition, documentation must be provided that the patient is unable to tolerate ursodiol (ursodeoxycholic acid) or that the patient had an inadequate response to at least 12 months of ursodiol treatment. Inadequate response to ursodiol is defined as ALP greater than 1.67 times the upper limit of normal (ULN equals 118 u/L for females and 124 u/L for males) or total bilirubin level that is greater than 1 time the ULN, but less than 2 times upper limit of normal (ULN equals 1.1 mg/dL for females and 1.5 mg/dL for males). For patients who are unable to tolerate ursodiol, Ocaliva will be covered as monotherapy. For patients who had an inadequate response to ursodiol, Ocaliva will be covered when prescribed in combination with ursodiol. Upon recertification, there must be documentation of subjective and/or objective evidence the patient has experienced improvement of symptoms and/or appropriate lab values due to Ocaliva. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |



# ofev

---

## Products Affected

- OFEV

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Documentation of diagnosis, pertinent lab/diagnostic test results to confirm diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | For a diagnosis of Idiopathic Pulmonary Fibrosis, must be prescribed by a Pulmonologist. For Systemic Sclerosis-Associated Interstitial Lung disease with declining pulmonary function or chronic fibrosing interstitial lung diseases with a progressive phenotype, must be prescribed by a Pulmonologist or Rheumatologist. |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | UNDER CMS REVIEW  |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# onychomycosis

## Products Affected

- *tavaborole*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Documentation of diagnosis, KOH stain or culture results showing presence of trichophyton rubrum or trichophyton mentagrophytes, and documentation of previous therapies  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for the treatment of onychomycosis of the toenails in patients with documented culture or KOH stain positive for Trichophyton rubrum or Trichophyton mentagrophytes. Additionally, unless contraindicated, documentation of failure or severe intolerance to a course of oral terbinafine must be provided. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# opioid-induced constipation

---

## Products Affected

- RELISTOR ORAL
- RELISTOR SUBCUTANEOUS SOLUTION
- RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML, 8 MG/0.4 ML
- SYMPROIC

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for the treatment of opioid-induced constipation with documented lack of response or severe intolerance to generic lubiprostone or Movantik. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# opzelura

## Products Affected

- OPZELURA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling, specifically not to be used in combination with therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine. Excluded for forms of vitiligo other than nonsegmental.   |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a dermatologist.   |
| <b>Coverage Duration</b>            | Initial 6 months, recert 1 year.   |
| <b>Other Criteria</b>               | Covered for a diagnosis of nonsegmental vitiligo in patients for whom a two-month trial with prescription strength generic topical steroids has failed to restore pigmentation to the vitiliginous skin. For patients with vitiliginous skin on the face and/or intertriginous areas where topical steroids would be inappropriate, failure of a two-month trial with topical tacrolimus to restore pigmentation to the vitiliginous skin must be documented. Covered for a diagnosis of atopic dermatitis in patients who have had serious side effects from or drug failure after at least a four-week trial with a prescription strength generic topical steroid. Must also have had serious side effects from or drug failure after at least a six-week trial with either topical tacrolimus or topical pimecrolimus. Recertification for a diagnosis of nonsegmental vitiligo will require documentation of improvement/decrease in affected areas of vitiligo from baseline based on objective and/or subjective assessment from provider. Recertification for atopic dermatitis will require the patient has achieved/maintained a positive clinical response to therapy. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# oral oncology

---

## Products Affected

- *abiraterone*
- AKEEGA
- ALECENSA
- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLET DOSE PACK
- AUGTYRO
- AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG
- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG
- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG
- CABOMETYX
- CAPRELSA ORAL TABLET 100 MG, 300 MG
- COMETRIQ
- COPIKTRA
- DAURISMO ORAL TABLET 100 MG, 25 MG
- ERIVEDGE
- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus oral tablet for suspension 2 mg, 3 mg, 5 mg*
- FOTIVDA
- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG
- GAVRETO
- *gefitinib*
- GILOTRIF
- ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG
- IDHIFA
- *imatinib oral tablet 100 mg, 400 mg*
- INLYTA ORAL TABLET 1 MG, 5 MG
- INQOVI
- INREBIC
- IWILFIN
- JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG
- JAYPIRCA ORAL TABLET 100 MG, 50 MG
- KOSELUGO
- KRAZATI
- *lapatinib*
- *lenalidomide*
- LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY (10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X 2), 20 MG/DAY (10 MG X 2), 24 MG/DAY (10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2)
- LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG
- MG
- LORBRENA ORAL TABLET 100 MG, 25 MG
- LUMAKRAS
- LYNPARZA
- LYTGABI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5)
- NERLYNX
- NINLARO
- NUBEQA
- ODOMZO
- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG
- OJEMDA
- OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG
- ONUREG
- ORSERDU ORAL TABLET 345 MG, 86 MG
- *pazopanib*
- PEMAZYRE
- PIQRAY
- POMALYST
- QINLOCK
- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG
- REZLIDHIA
- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG
- ROZLYTREK ORAL PELLETS IN PACKET
- RUBRACA
- RYDAPT
- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG
- *sorafenib*
- SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG
- STIVARGA
- *sunitinib malate*
- TABRECTA
- TAGRISSO
- TALZENNA
- TASIGNA
- TAZVERIK
- TEPMETKO
- TIBSOVO
- TRUQAP
- TUKYSA ORAL TABLET 150 MG, 50 MG
- TURALIO ORAL CAPSULE 125 MG
- VANFLYTA
- VENCLEXTA ORAL TABLET 10 MG, 100 MG,

- 50 MG
- VENCLEXTA STARTING PACK
- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION
- VIZIMPRO
- VONJO
- XALKORI
- XOSPATA
- XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1),

- 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)
- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG
- ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG
- ZOLINZA
- ZYDELIG
- ZYKADIA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | For cancer diagnosis, must be prescribed by an oncologist or hematologist, or urologist in the case of prostate cancer. For non-cancer diagnosis, must be prescribed by an appropriate specialist. |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements.  |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# orencia

## Products Affected

- ORENCIA (WITH MALTOSE)
- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling. Orencia will not be approved for use in combination with other potent immunosuppressants, such as biologic DMARDs or Janus Kinase inhibitors.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an appropriate specialist to treat the stated diagnosis.  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for prophylaxis of acute graft versus host disease (in combination with a calcineurin inhibitor and methotrexate) in adults and pediatric patients at least 2 years of age undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor. Covered for the treatment of psoriatic arthritis. Covered for the treatment of active moderate to severe rheumatoid arthritis or juvenile idiopathic arthritis in patients with polyarticular disease who have intolerance or failure to respond to one of the following approved disease-modifying antirheumatic drug (DMARD) agents, such as methotrexate, azathioprine, sulfasalazine, or hydroxychloroquine, either alone or in combination for a 3-month period. Orencia will not be approved for use in combination with other potent immunosuppressants, such as biologic DMARDs or Janus Kinase inhibitors. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# orgovyx

---

## Products Affected

- ORGOVYX

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an oncologist or hematologist.   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Orgovyx will be covered for patients with advanced Prostate Cancer who have a contraindication (such as high risk for cardiovascular [CV] events or a history of CV events) or had serious side effects to two of the following: degarelix (Firmagon), leuprolide (Lupron/Eligard), or triptorelin/Trelstar. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |



# oriahnn

## Products Affected

- ORIAHNN

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, uterine fibroids must be documented by pelvic ultrasound  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a gynecologist   |
| <b>Coverage Duration</b>            | Initial approval - 1 year. Recertification - 1 year.   |
| <b>Other Criteria</b>               | Covered for premenopausal female patients with a diagnosis of heavy menstrual bleeding associated with uterine fibroids. Pelvic ultrasound must be provided to confirm diagnosis. Patient must have had serious side effects or drug failure with a contraceptive (such as estrogen-progesterone, progesterone, or hormone-based intrauterine device) and tranexamic acid. Recertification will require objective and/or subjective evidence from provider of improved symptoms. Treatment beyond 24 months (two 12-month courses) will not be approved. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# orilissa

---

## Products Affected

- ORILISSA ORAL TABLET 150 MG, 200 MG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Excluded for patients with severe hepatic impairment (Child-Pugh C) and as limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a gynecologist   |
| <b>Coverage Duration</b>            | Dyspareunia/moderate hepatic impairment: 6 mos max. Other: auth 6 mos, recert 18 mos. (24 mos max)   |
| <b>Other Criteria</b>               | Covered for a diagnosis of pain associated with endometriosis. In addition, the patient must have a lack of clinical response, intolerance, or contraindication to at least one prescription strength nonsteroidal anti-inflammatory drug (NSAID) used in combination with hormonal therapy. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# orkambi

---

## Products Affected

- ORKAMBI ORAL GRANULES IN PACKET
- ORKAMBI ORAL TABLET

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Coverage will be excluded in patients with Cystic Fibrosis who are not homozygous for the F508del mutation in the CFTR gene.   |
| <b>Required Medical Information</b> | Documentation of diagnosis, pertinent lab/diagnostic results to include testing that shows two copies of the F508 del mutation in the conductance regulator (CFTR) gene. |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements.  |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# otezla

## Products Affected

- OTEZLA
- OTEZLA STARTER ORAL TABLET DOSE  
PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG  
(4)-30 MG (47)

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | For Psoriatic Arthritis and Plaque Psoriasis, prescriber must be a Dermatologist or Rheumatologist   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Otezla is covered for the diagnosis of oral ulcers associated with Bechet's disease. Covered for patients with a diagnosis of mild, moderate, or severe chronic plaque psoriasis that involves at least 2% body surface area. Covered for the diagnosis of mild, moderate, or severe chronic plaque psoriasis in patients if the affected area involves the hands, feet, facial or genital regions. Patients also must meet one of the following criteria: 1) had a 3-month trial of acitretin, methotrexate, or cyclosporine therapy resulting in intolerance or clinical failure or 2) have tried UVB/coal tar or PUVA/topical corticosteroids for at least 3 months or 3) have tried and failed at least two of the following for 3 months: treatment with medium and/or high potency topical corticosteroids or anthralin, calcipotriene, or tazarotene. Otezla is covered for patients with a diagnosis of psoriatic arthritis. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# oxbryta

## Products Affected

- OXBRYTA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | Initial approval - 1 year. Recertifications - 2 years.  |
| <b>Other Criteria</b>               | Covered for treatment of sickle cell disease in patients who have had at least one prior vaso-occlusive crises (VOC) in previous 12 months. Examples of VOC events include, but are not limited to, acute episode of pain caused by VOC, acute chest syndrome, hepatic sequestration, splenic sequestration, or priapism. In addition, patient must have experienced inadequate pain relief with a minimum three-month trial or a hematologic toxicity reaction with hydroxyurea. Hematologic toxicity with hydroxyurea is defined by neutrophil, platelet, hemoglobin and/or reticulocyte count abnormalities concurrent with hydroxyurea use. Recertification after initial one year approval requires evidence of a decrease in VOC frequency from baseline, attributable to use of Oxbryta. Subsequent recertifications require evidence of ongoing decreased VOC frequency from baseline. Requires requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# pain management

---

## Products Affected

- *fentanyl citrate buccal lozenge on a handle*
- *fentanyl citrate buccal effervescent tab 200 mcg, 400 mcg, 600 mcg, 800 mcg*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for the management of breakthrough pain in individuals with cancer that are opioid-tolerant. In addition, there must be documentation of failure or severe intolerance to at least two other opioid medications. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# parkinsons

## Products Affected

- GOCOVRI ORAL 24-H ER CAP 137 MG, 68.5 MG
- INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE
- NOURIANZ

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | For the treatment of off episodes in Parkinson's disease, Gocovri, Inbrija, and Nourianz are covered for patients who have had inadequate therapeutic response or severe intolerance to TWO generic anti-Parkinson's disease drugs with different mechanisms of action. Examples include COMT inhibitors (entacapone and tolcapone), dopamine agonists (pramipexole, ropinirole, amantadine, and bromocriptine), MAO B-inhibitors (rasagiline and selegiline), and anticholinergics (benztropine). For the treatment of dyskinesia associated with Parkinson's disease, Gocovri is covered in combination with levodopa/carbidopa in patients who have had inadequate response with or severe intolerance to immediate-release amantadine. Recertification for the treatment of off episodes will require objective and/or subjective evidence from prescriber of a decrease in frequency and/or severity of wearing-off symptoms. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# pirfenidone

---

## Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Documentation of diagnosis, pertinent lab/diagnostic test results to confirm diagnosis. |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.          |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a pulmonologist.  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for a documented diagnosis of idiopathic pulmonary fibrosis.                    |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |



# procysbi

---

## Products Affected

- PROCYSBI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Hypersensitivity to penicillamine and as limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a nephrologist, genetic or metabolic specialist  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for a diagnosis of nephropathic cystinosis in patients who have demonstrated therapeutic failure, contraindication, or intolerance to immediate release cysteamine/Cystagon. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# promacta

## Products Affected

- PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG
- PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | For ITP or aplastic anemia, must be prescribed by a Hematologist. For thrombocytopenia with Hep C, must be prescribed by GI, Hepatologist, Infectious Disease, or HCV/HIV specialist.  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for a diagnosis of chronic immune thrombocytopenia purpura (ITP) in patients who have experienced an insufficient response to previous treatment with either corticosteroids or immunoglobulins (IVIG). Insufficient response is defined as a platelet count of less than 30,000/microliter or greater than 30,000/microliter but with bleeding symptoms. Covered for a diagnosis of thrombocytopenia in patients with chronic Hepatitis C to allow initiation and maintenance of interferon-based therapy. Covered for first-line treatment of severe aplastic anemia, in combination with standard immunosuppressive therapy. Covered for severe refractory aplastic anemia in patients who have experienced an insufficient response to immunosuppressive therapy (such as antithymocyte globulin (ATG) alone or in combination with cyclosporine and/or a corticosteroid). Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | Yes  |

# prophylactic hae

## Products Affected

- HAEGARDA
- TAKHZYRO SUBCUTANEOUS SOLUTION
- TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML (150 MG/ML)

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Excluded for acute hereditary angioedema attacks.  |
| <b>Required Medical Information</b> | UNDER CMS REVIEW   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by allergist, immunologist, hematologist, or dermatologist  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for a confirmed diagnosis of HAE type 1, type II, or type III. Prophylactic therapy will be covered for individuals whose provider has determined that prophylactic therapy is medically necessary, after consideration of such factors as disease burden, activity of disease, frequency of attacks, patient preference, quality of life, and availability of healthcare resources. Objective and/or subjective documentation of these considerations must be provided. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# pulmonary hypertension

## Products Affected

- ADEMPAS
- *ambrisentan oral tablet 10 mg, 5 mg*
- *bosentan oral tablet 125 mg, 62.5 mg*
- OPSUMIT
- OPSYNOVI
- ORENITRAM
- ORENITRAM MONTH 1 TITRATION KT
- ORENITRAM MONTH 2 TITRATION KT
- ORENITRAM MONTH 3 TITRATION KT
- *sildenafil (pulmonary hypertension) oral tablet*
- *tadalafil (pulmonary hypertension)*
- TYVASO
- TYVASO INSTITUTIONAL START KIT
- TYVASO REFILL KIT
- TYVASO STARTER KIT
- UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- UPTRAVI ORAL TABLET DOSE PACK

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, right heart catheterization results if PAH   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a pulmonologist or cardiologist   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Required for all drugs for pulmonary arterial hypertension (PAH) indication: right heart catheterization showing a mean artery pressure of greater than or equal to 25 mmHg at rest, pulmonary capillary wedge pressure less than or equal to 15 mmHg at rest. Additionally, coverage of Adempas, Orenitram, and Uptravi for PAH require trial with a generic formulary phosphodiesterase-5 enzyme inhibitor (PDE5i) (sildenafil, tadalafil) AND a generic formulary endothelin receptor antagonist (ERA) (ambrisentan, bosentan). Adempas covered for chronic thromboembolic pulmonary hypertension (CTEPH). Opsumit and Opsynvi require a trial with a generic ERA (ambrisentan, bosentan). Recertification requires objective and/or subjective clinical evidence of disease improvement attributed to use of approved drug(s). Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. Nebulized products will also be evaluated for part B versus part D coverage. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# pyrukynd

---

## Products Affected

- PYRUKYND ORAL TABLET 20 MG, 5 MG, 5 MG (4-WEEK PACK), 50 MG
- PYRUKYND ORAL TABLET DOSE PACK

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling. Also, Pyrukynd will not be covered for patients who are homozygous for the c.1436G to A (p.R479H) variant or have 2 non-missense variants (without the presence of another missense variant) in the PKLR gene. |
| <b>Required Medical Information</b> | Diagnosis, including supporting labs/diagnostic test results.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a hematologist, geneticist, or provider who specializes in pyruvate kinase (PK) deficiency   |
| <b>Coverage Duration</b>            | 6 months   |
| <b>Other Criteria</b>               | UNDER CMS REVIEW   |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# quinine sulfate

---

## Products Affected

- *quinine sulfate*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Excluded for the treatment of leg cramps.                                      |
| <b>Required Medical Information</b> | Diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis. |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | 6 months   |
| <b>Other Criteria</b>               | Quinine sulfate is covered for the treatment of malaria infections.            |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# radicava

---

## Products Affected

- RADICAVA ORS STARTER KIT SUSPENSION

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, including supporting labs/diagnostic test results.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by or in consultation with a provider that specializes in Amyotrophic lateral sclerosis (ALS) and/or neuromuscular disorders  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for a diagnosis of Amyotrophic Lateral Sclerosis (ALS) in adult patients. Recertification requires subjective or objective evidence from provider that use of Radicava has improved the patient's condition. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# recorlev

## Products Affected

- RECORLEV

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling. Excluded for individuals with pituitary or adrenal carcinoma and will not be covered for a treatment of fungal infections.  |
| <b>Required Medical Information</b> | Diagnosis, mean urinary free cortisol (UFC) level measured over three 24-hour measurements, current and previous therapies used for the treatment of the stated diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an endocrinologist.   |
| <b>Coverage Duration</b>            | Initial approval - 6 months. Recertifications - 1 year.   |
| <b>Other Criteria</b>               | Covered for a diagnosis of endogenous Cushing's syndrome in patients with documentation of clinical symptoms (such as diabetes, central obesity, moon face, buffalo hump, osteoporosis, muscle wasting, hypertension, depression, and anxiety) who have a mean urinary free cortisol (UFC) level that is at least 1.5x the upper limit of normal (ULN) measured over three 24-hour measurements (ULN = 50 mcg/24 hours or 138 nmol/24 hours). Also, there must be documentation of failure of or contraindication to Cushing's syndrome-specific surgery as well as serious side effects or drug failure with oral ketoconazole. For patients with a diagnosis of Cushing's Disease (Cushing's Syndrome that is caused by a pituitary adenoma), documentation of trial and failure or serious side effects with Signifor/pasireotide must be provided. Recertification at 6 months and yearly thereafter will require laboratory results to document a recent UFC level within normal limits AND improvement in symptoms of Cushing's Syndrome. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |



# REZUROCK

## Products Affected

- REZUROCK

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a healthcare provider experienced in the management of transplant rejection and/or graft-versus-host disease.  |
| <b>Coverage Duration</b>            | Initial approval - 6 months. Recertifications - 2 years.   |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of chronic graft-versus-host disease (cGVHD) who have had inadequate response or intolerance with at least 2 prior lines of therapy, one of which must be Imbruvica/ibrutinib. For patients on a proton pump inhibitor (PPI) (e.g., omeprazole, esomeprazole, lansoprazole), an attempt must be made to discontinue the PPI and switch to an H2 receptor antagonist (e.g., famotidine) to allow for once daily dosing of Rezurock. Upon recert, documentation of positive response to therapy must be provided. Positive response is defined as resolution of all manifestations in each organ or site, or improvement in at least one organ or site without progression in any other organ or site. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# rinvoq

---

## Products Affected

- RINVOQ ORAL 24-H ER TAB 15 MG, 30 MG, 45 MG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, concurrent medications, previous drugs tried.                                  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.            |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an allergist, dermatologist, gastroenterologist, or rheumatologist. |
| <b>Coverage Duration</b>            | One year  |

| PA Criteria                | Criteria Details  |
|----------------------------|---|
| <b>Other Criteria</b>      | <p>Covered for ANKYLOSING SPONDYLITIS (AS) in pts who have had serious side effects or drug failure w/ one of the following: Hadlima or Enbrel. TNF-blocker-experienced pts must have had serious side effects or drug failure with any AS-indicated TNF-blocker. Covered for moderate to severe ATOPIC DERMATITIS (AD) involving at least 10% body surface area (BSA). In addition, pt must have received treatment with TWO of the following treatment options during the six months preceding the request: 1) treatment with high-potency topical steroid for minimum 14-day duration or treatment with medium potency topical steroid for minimum 28-day duration, 2) treatment w/ topical tacrolimus, 3) treatment w/ an oral or injectable immunosuppressant, such as a steroid indicated or compendia-supported for treatment of AD, 4) treatment with systemic therapy indicated or compendia-supported for treatment of AD. Covered for moderately to severely active CROHN'S DISEASE (CD) or ULCERATIVE COLITIS (UC) who have had serious side effects or drug failure with Hadlima. TNF-blocker-experienced patients must have had serious side effects or drug failure with any Crohn's or UC-indicated TNF-blocker. Covered for the diagnosis of NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. Covered for PSORIATIC ARTHRITIS (PsA) in pts who have had serious side effects or drug failure with either Hadlima or Enbrel. TNF-blocker-experienced pts must have had serious side effects or drug failure with any PSA-indicated TNF-blocker. Covered for active moderate to severe RHEUMATOID ARTHRITIS (RA) in pts who have failed to respond to or are intolerant of approved disease modifying anti-rheumatic drug (DMARD) agents, such as methotrexate, azathioprine, sulfasalazine, or hydroxychloroquine, either alone or in combination, for a 3-month period. In addition, the patient must have had serious side effects or drug failure with either Hadlima or Enbrel. TNF-blocker-experienced patients must have had serious side effects or drug failure with any RA-indicated TNF-blocker. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements.</p> |
| <b>Indications</b>         | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>      |   |
| <b>Part B Prerequisite</b> | No  |

# samsca

---

## Products Affected

- *tolvaptan oral tablet 15 mg, 30 mg*

| <b>PA Criteria</b>                  | <b>Criteria Details</b>   |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# sapropterin

## Products Affected

- *sapropterin*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, baseline serum phenylalanine level, current/recent phenylalanine level with each recertification  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | Initial approval - 2 months. Recertifications - 1 year.  |
| <b>Other Criteria</b>               | Covered as adjunct therapy for patients diagnosed with phenylketonuria (PKU). Initial approval will be for 2 months. Phenylalanine (PHE) levels should be checked one week after initiation of therapy. If PHE levels do not decrease from baseline on a 10mg/kg/day dose, the dose may be increased to 20mg/kg/day. If PHE levels do not decrease from baseline after 2 months, the patient is considered a non-responder and further therapy will not be authorized. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# SCIG

## Products Affected

- HIZENTRA
- HYQVIA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | DIAGNOSIS, CURRENT AND PREVIOUS THERAPIES FOR STATED DIAGNOSIS (IF APPLICABLE). WHILE NO SPECIFIC LAB/DIAGNOSTIC TESTS REQUIRED, PROVIDING THE RESULTS USED TO DIAGNOSE THE CONDITION IS RECOMMENDED, THEREBY REDUCING THE LIKELIHOOD THAT ADDITIONAL INFORMATION WILL BE NEEDED TO PROCESS THE REQUEST. |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | TWO YEARS FOR CHRONIC CONDITIONS. ONE MONTH FOR ACUTE CONDITIONS. 5 DAYS FOR GUILLAIN-BARRE  |
| <b>Other Criteria</b>               | REQUESTS WILL BE EVALUATED FOR PART B VS PART D COVERAGE. REQUESTS FOR NON-FDA APPROVED INDICATIONS WILL BE EVALUATED ACCORDING TO THE MEDICARE STATUTORY OFF LABEL USE REQUIREMENTS.  |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# signifor

## Products Affected

- SIGNIFOR

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Documentation of diagnosis. For the diagnosis of Cushings disease, there must be pertinent lab/diagnostic test results, which include a mean urine free cortisol (mUFC) level at baseline and upon recertification. Confirmation from provider that patient is not a candidate for surgery or that previous surgery was not effective. A non-surgical candidate is defined as either having a medical contraindication to surgery or having a tumor which is surgically unapproachable. |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an endocrinologist.   |
| <b>Coverage Duration</b>            | Initial approval - 3 months. Recertifications - 1 year.   |
| <b>Other Criteria</b>               | After 3 months of therapy for a diagnosis of Cushings disease, patient must demonstrate a reduction in mUFC compared to baseline. Subsequent authorizations will be for 12 months with continued signs of efficacy. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements.   |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# simlandi

---

## Products Affected

- SIMLANDI (CITRATE-FREE) AUTOINJECTOR

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis. |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.            |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an appropriate specialist to treat the stated diagnosis.            |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | UNDER CMS REVIEW  |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |



# sivextro

---

## Products Affected

- SIVEXTRO

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Documentation of diagnosis, pertinent lab/diagnostic test results (such as bacterial cultures or antibiotic sensitivity testing), and documentation of previous therapies  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | 6 days   |
| <b>Other Criteria</b>               | Sivextro is covered when prescribed or recommended by an Infectious Disease specialist. When prescribed by any other prescriber, laboratory data including culture site, organism identified and susceptibility must accompany prior-authorization request and documentation must support the trial. In addition, documentation of therapeutic failure of at least one first-line antibacterial agent that is clinically appropriate for the organism identified must be submitted. Approval will be for 6 days of therapy. Requests for non-FDA approved durations of therapy will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# skyclarys

---

## Products Affected

- SKYCLARYS

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic/genetic test results. Baseline modified Friedreichs Ataxia Rating Scale (mFARS) score must be provided.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist or prescriber knowledgeable in the management of Friedreichs ataxia (FA).   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of Friedreichs ataxia confirmed by genetic testing. In addition, the patient must exhibit clinical manifestations of disease (e.g., muscle weakness, decline in coordination, frequent falling). Recertification requests will require documentation that the patient has had a clinical benefit from therapy (e.g., slowed decline in limb coordination) OR patient has had a reduction in modified Friedreichs Ataxia Rating Scale (mFARS) score of at least 1.5 points from baseline OR provider attestation that the patient continues to benefit from therapy. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# skyrizi

## Products Affected

- SKYRIZI SUBCUTANEOUS PEN INJECTOR MG/2.4 ML (150 MG/ML)
- SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML
- SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a dermatologist, gastroenterologist, or rheumatologist.   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for a diagnosis of moderately to severely active Crohn's Disease in patients who have failed to achieve remission with at least 6 weeks of corticosteroid treatment or in corticosteroid dependent or refractory patients who fail to maintain remission with an immunomodulator (such as azathioprine, 6-mp, or MTX). Covered for patients with a diagnosis of moderate to severe chronic plaque psoriasis that involves at least 5% body surface area. Covered for the diagnosis of moderate to severe chronic plaque psoriasis in patients with less than 5% BSA if the affected area involves the hands, feet, facial or genital regions. Patients also must meet one of the following criteria: 1) had a 3-month trial of acitretin, methotrexate, or cyclosporine therapy resulting in intolerance or clinical failure or 2) have tried UVB/coal tar or PUVA/topical corticosteroids for at least 3 months or 3) have tried and failed at least two of the following for 3 months: treatment with medium and/or high potency topical corticosteroids or anthralin, calcipotriene, or tazarotene. Covered for the treatment of active psoriatic arthritis. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# sleep disorders

## Products Affected

- *armodafinil*
- *modafinil oral tablet 100 mg, 200 mg*
- SUNOSI ORAL TABLET 150 MG, 75 MG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, sleep study results, and documentation of outcome with previous therapies attempted for the stated diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist or sleep specialist for a diagnosis of cataplexy or excessive daytime sleepiness associated with narcolepsy. Must be prescribed by a neurologist, sleep specialist, or pulmonologist for a diagnosis of Excessive Daytime Sleepiness associated with Obstructive Sleep Apnea.   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Armodafinil and modafinil are covered for a diagnosis of excessive daytime sleepiness associated with narcolepsy, excessive daytime sleepiness associated with obstructive sleep apnea (OSA) and shift-work disorder. Sunosi is covered for a diagnosis of excessive daytime sleepiness associated with narcolepsy for adult patients who have had severe intolerance to or therapeutic failure of both armodafinil and modafinil (armodafinil and modafinil not required in pediatric patients). Sunosi is covered for a diagnosis of excessive daytime sleepiness associated with obstructive sleep apnea (OSA) for patients who have had severe intolerance to or therapeutic failure of both armodafinil and modafinil. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# sodium oxybate

---

## Products Affected

- *sodium oxybate*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, sleep study results, and documentation of outcome with previous therapies attempted for the stated diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a neurologist or sleep specialist for a diagnosis of cataplexy or excessive daytime sleepiness associated with narcolepsy. Must be prescribed by a neurologist, sleep specialist, or pulmonologist for a diagnosis of Excessive Daytime Sleepiness associated with Obstructive Sleep Apnea. |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | UNDER CMS REVIEW  |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# stelara

---

## Products Affected

- STELARA SUBCUTANEOUS

| <b>PA Criteria</b>                  | <b>Criteria Details</b>   |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis. |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.            |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an appropriate specialist to treat the stated diagnosis.            |
| <b>Coverage Duration</b>            | One year  |

| PA Criteria                | Criteria Details  |
|----------------------------|---|
| <b>Other Criteria</b>      | <p>Covered for a diagnosis of moderate to severe active Crohn's disease. In addition, the patient must meet one of the following criteria: 1) patient continues to experience disease flare despite complete and adequate therapy with a corticosteroid. 2) treatment with an immunomodulator (such as azathioprine or 6-mp) fails to maintain remission in a case of steroid-dependent or steroid-refractory disease. 3) documentation is provided that azathioprine, 6-mp, or methotrexate is not effective, contraindicated, or not tolerated. Covered for patients with a diagnosis of moderate to severe chronic plaque psoriasis that involves at least 5% body surface area. Covered for the diagnosis of moderate to severe chronic plaque psoriasis in patients with less than 5% BSA if the affected area involves the hands, feet, facial or genital regions. Patients also must meet one of the following criteria: 1) had a 3-month trial of acitretin, methotrexate, or cyclosporine therapy resulting in intolerance or clinical failure or 2) have tried UVB/coal tar or PUVA/topical corticosteroids for at least 3 months or 3) have tried and failed at least two of the following for 3 months: treatment with medium and/or high potency topical corticosteroids or anthralin, calcipotriene, or tazarotene. Covered for the diagnosis of psoriatic arthritis. Covered for the diagnosis of moderately to severely ulcerative colitis in patients with documented failure of TWO standard of care classes: thiopurine, 5-aminosalicylate, cyclosporine, or IV/oral steroids. DOSING: For patients with a diagnosis of psoriasis weighing less than or equal to 100kg, 45mg dose will be approved. For patients with a diagnosis of psoriasis weighing greater than 100kg, 90mg dose will be approved. For patients with a diagnosis of psoriatic arthritis, 45mg dose will be approved. Initial dosing for psoriasis and psoriatic arthritis is at weeks 0, 4, 12 and then every 12 weeks thereafter. For patients with coexistent psoriatic arthritis and moderate to severe plaque psoriasis and who weigh more than 100kg, a 90mg starting dose will be authorized. Initial dosing is at weeks 0, 4, 12 and then every 12 weeks thereafter. For patients with Crohn's disease, weight-dependent induction dosing at week zero and the maintenance dose of 90mg every 8 weeks thereafter will be authorized.</p> |
| <b>Indications</b>         | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>      |   |
| <b>Part B Prerequisite</b> | No  |

# symdeko

## Products Affected

- SYMDEKO ORAL SEQUENTIAL TAB 100-150 MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N)

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Coverage will be excluded in patients that lack the required genetic mutation(s) targeted by the medication.  |
| <b>Required Medical Information</b> | Documentation of diagnosis, pertinent lab/diagnostic results to include testing that shows either two copies of the F508 del mutation in the conductance regulator (CFTR) gene or at least one mutation in the CFTR gene that is responsive to tezacaftor/ivacaftor (Symdeko). Responsive mutations are those outlined in FDA labeling. |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements.   |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |



# syndros

---

## Products Affected

- SYNDROS

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis. For a diagnosis of nausea and vomiting associated with cancer chemotherapy, also list previous therapies.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | Anorexia due to AIDS - 1 year. Chemo-induced nausea/vomiting - 6 months.   |
| <b>Other Criteria</b>               | Covered for the treatment of nausea and vomiting associated with cancer chemotherapy with documented lack of response or severe intolerance to one 5HT-3 receptor antagonist. Covered for treatment of anorexia associated with weight loss in patients with AIDS. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# tadalafil for daily use

---

## Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg (generic for cialis)*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Tadalafil for daily use will not be covered for the independent diagnosis of Erectile Dysfunction. Tadalafil is excluded for off-label indications even if supported by AHFS or DrugDex compendia. |
| <b>Required Medical Information</b> | Diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for a diagnosis of benign prostatic hyperplasia (BPH).   |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# tafamidis

## Products Affected

- VYNDAMAX
- VYNDAQEL

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, pertinent lab/diagnostic tests, including tests confirming presence of TTR amyloid in cardiac tissue such as 99m Technetium-labeled pyrophosphate cardiac imaging test results (nuclear scintigraphy) positive for TTR amyloid or genetic testing/next-generation sequencing confirming a variant TTR genotype and/or TTR precursor protein  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a specialist experienced in the diagnosis of Transthyretin-mediated Amyloidosis (ATTR-CM), such as a cardiologist   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of cardiomyopathy of wild-type (wtATTR-CM) or Hereditary Transthyretin-mediated Amyloidosis (hATTR-CM). Patient must have a medical history of NYHA class I-III heart failure with at least one prior hospitalization for heart failure or clinical evidence of heart failure requiring treatment with a diuretic for improvement. Evidence of cardiac involvement seen on echocardiography and/or cardiac magnetic imaging, such as thickened left ventricle wall or septum, must be provided. Presence of TTR amyloid in cardiac tissue must be confirmed via 99m Technetium-labeled pyrophosphate cardiac imaging test results (nuclear scintigraphy) positive for TTR amyloid or via genetic testing/next-generation sequencing confirming a variant TTR genotype and/or TTR precursor protein correlated with amyloid deposits identified on cardiac biopsy. Upon recertification, there must be documentation that the patient continues to obtain clinical benefit from the therapy. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# tarpeyo

## Products Affected

- TARPEYO

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a nephrologist or provider specializing in IgA nephropathy   |
| <b>Coverage Duration</b>            | 10 months  |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of primary immunoglobulin A nephropathy (IgAN), confirmed on biopsy. Patient must have an eGFR greater than 35mL/min/1.73m <sup>2</sup> and have proteinuria (defined as greater than or equal to 1 g/day or urine protein creatinine ratio (UPCR) greater than or equal to 0.8 g/g). Patient must also be on an ACE Inhibitor (ACE-I) or Angiotensin II Receptor Blocker (ARB) at the maximally tolerated dose, unless the patient is unable to tolerate or drug class is contraindicated. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# tasimelteon

## Products Affected

- *tasimelteon*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, including supporting lab/diagnostic test results (such as urinary melatonin and/or cortisol levels or actigraphy over a several week interval). For Smith-Magenis Syndrome (SMS), appropriate genetic testing is also required.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a sleep specialist or neurologist.  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for a diagnosis of non-24-hour sleep-wake disorder for blind individuals who lack light perception. Based on the patient population used in clinical studies evaluating the efficacy of tasimelteon capsules will only be approved in patients with non-24 who are totally blind. Covered for nighttime sleep disturbances in Smith-Magenis syndrome (SMS). For SMS, patients must provide genetic testing confirmation of chromosome 17p11.2 deletion or RAI1 gene mutation. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# tavneos

## Products Affected

- TAVNEOS

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis. Must either have a positive test for antibodies to proteinase 3 (PR3) or myeloperoxidase (MPO) or have histological evidence of GPA or MPA via biopsy.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a rheumatologist, nephrologist, pulmonologist, or immunologist.  |
| <b>Coverage Duration</b>            | Initial approval - 6 months. Recertifications - 1 year.  |
| <b>Other Criteria</b>               | Covered as adjunctive treatment for patients with a diagnosis of active and severe anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (granulomatosis with polyangiitis [GPA] or microscopic polyangiitis [MPA]). Tavneos must be used as adjunctive treatment in combination with standard of care therapy (such as cyclophosphamide, azathioprine, mycophenolate mofetil, rituximab, glucocorticoids). Recertification will require documentation of disease remission, defined as the absence of clinical signs or symptoms attributed to GPA or MPA while on Tavneos. Recertification requires that Tavneos continue to be used in combination with standard of care therapy. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# teriparatide

## Products Affected

- *teriparatide subcutaneous pen injector 20 mcg/dose (620mcg/2.48ml)*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, DEXA scan report(s), previous therapies  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | Two years (refer to other criteria section)   |
| <b>Other Criteria</b>               | <p>Patient must fall into one of the following categories: postmenopausal woman, primary or hypogonadal osteoporosis in a male or patient at risk for steroid induced osteoporosis. Patient must also be at high risk for a fracture defined as 1) history of previous osteoporosis-related fracture, 2) T-score of -2.5 SD or less, 3) T-score between -1.0 and -2.5 SD below normal and a FRAX score for hip fracture of 3% or greater or the risk for other bone fracture is 20% or greater. Patient must also have experienced therapeutic failure, severe intolerance or a contraindication to an oral bisphosphonate or be an inappropriate candidate for oral bisphosphonate therapy based on clinical presentation. Therapeutic failure is defined as a decrease in bone mineral density or a fracture while on bisphosphonate therapy. Severe intolerance defined as chest pain, difficulty swallowing, intense abdominal pain, or chronic dyspepsia when oral bisphosphonate therapy was taken according to manufacturer recommendations. Oral bisphosphonates may be clinically inappropriate for a patient that is bed-ridden/unable to sit upright for 30 minutes unsupervised or has esophageal ulcerations, esophageal stricture, Barrett's esophagitis, or active ulcers. In patients without a trial of or contraindication to oral bisphosphonates, a trial with an injectable bisphosphonate will be accepted in lieu of oral, but is not required. Use of teriparatide for more than 2 years during a patient's lifetime should only be considered if a patient remains at or has returned to having a high risk for fracture. Requests for continued therapy beyond 2 years will require provider attestation that the patient has remained at or has returned to having a high risk for fracture. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements.</p> |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |

| <b>PA Criteria</b>             | <b>Criteria Details</b> |
|--------------------------------|-------------------------|
| <b>Part B<br/>Prerequisite</b> | No                      |



# thalomid

---

## Products Affected

- THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG

| <b>PA Criteria</b>                  | <b>Criteria Details</b>   |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# topical psoriasis combos

---

## Products Affected

- *calcipotriene-betamethasone*
- DUOBRII
- ENSTILAR

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for a diagnosis of Psoriasis. In addition, there must be lack of clinical response or intolerance to one topical steroid and either a topical vitamin D analog or a topical retinoid. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# topical retinoids

## Products Affected

- *adapalene topical cream*
- *adapalene topical gel 0.3 %*
- ALTRENO
- ARAZLO
- DIFFERIN TOPICAL LOTION
- FABIOR
- *tazarotene topical cream 0.1 %*
- *tazarotene topical foam*
- *tazarotene topical gel*
- *tretinoin*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Excluded when used for cosmetic purposes.  |
| <b>Required Medical Information</b> | Diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Adapalene, tazarotene, and tretinoin products will be approved for the diagnosis of acne vulgaris. In addition, tazarotene will be approved for the diagnosis of plaque psoriasis. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# TRIPTODUR

---

## Products Affected

- TRIPTODUR

| <b>PA Criteria</b>                  | <b>Criteria Details</b>   |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | ONE YEAR  |
| <b>Other Criteria</b>               | REQUESTS FOR NON-FDA APPROVED INDICATIONS WILL BE EVALUATED ACCORDING TO THE MEDICARE STATUTORY OFF-LABEL USE REQUIREMENTS. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# ursodiol

---

## Products Affected

- *ursodiol oral capsule 200 mg, 400 mg*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | None   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for the treatment of radiolucent, non-calcified gallstones in patients for whom elective cholecystectomy is medically inappropriate, as attested by provider. Covered for the prevention of gallstones in obese patients experiencing rapid weight loss. For all indications, documentation of contraindication to generic ursodiol 300 mg capsules and generic ursodiol tablets is required before the approval of ursodiol 200 mg and 400 mg capsules. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# valchlor

---

## Products Affected

- VALCHLOR

| <b>PA Criteria</b>                  | <b>Criteria Details</b>   |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | UNDER CMS REVIEW  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an oncologist or dermatologist.   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# verkazia

---

## Products Affected

- VERKAZIA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an ophthalmologist  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of vernal keratoconjunctivitis (VKC). The patient must have had serious side effects or drug failure to an ophthalmic antihistamine with mast cell stabilizer properties (such as olopatadine, azelastine, or epinastine) OR an antihistamine eye drop in combination with a mast cell stabilizer (such as cromolyn, Alocril or Alomide). In addition, the patient must have had persistent symptoms despite treatment with an ophthalmic steroid or an inability to titrate off ophthalmic steroids. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# verquvo

---

## Products Affected

- VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a Cardiologist  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for a diagnosis of symptomatic chronic heart failure with ejection fraction less than 45% in patients following a hospitalization for heart failure (within past 6 months) or need for outpatient IV diuretics (within past 3 months). Patient must also be stable on standard of care HF treatment (ARNI/ACE-I/ARB plus BB). Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |



# vijoice

---

## Products Affected

- VIJOICE ORAL GRANULES IN PACKET
- VIJOICE ORAL TABLET 125 MG, 250 MG/DAY (200 MG X1-50 MG X1), 50 MG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, including supporting labs/diagnostic test results.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an appropriate specialist to treat the stated diagnosis   |
| <b>Coverage Duration</b>            | Initial approval - 6 months. Recertifications - 1 year.   |
| <b>Other Criteria</b>               | Covered for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. There must be submitted documentation of a mutation in the PIK3CA gene and the patient must have at least one target lesion identified on imaging at baseline. Recertification will require documentation from provider of objective or subjective evidence that patient has derived clinical benefit from the use of Vijoice. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# vivjoa

## Products Affected

- VIVJOA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling. Vivjoa is contraindicated in those who have the ability to become pregnant, are pregnant, or are lactating.   |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis   |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | Limited to one treatment course (14 weeks) per year.  |
| <b>Other Criteria</b>               | Covered for a diagnosis of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential. Females who are not of reproductive potential are defined as persons who are biological females who are postmenopausal or have another reason for permanent infertility (e.g. tubal ligation, hysterectomy, salpingo-oophorectomy). The patient must have had 3 or more symptomatic acute episodes of VVC within the past 12 months and must have a KOH stain or other positive diagnostic culture test for this recurrence. In addition, the patient must have experienced an adverse reaction or treatment failure of oral fluconazole at a dosing regimen appropriate for diagnosis of RVVC, unless patient has adverse reaction or contraindication to fluconazole. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# voriconazole (IV)

---

## Products Affected

- *voriconazole intravenous*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling and excluded for any non-FDA approved or non-medically accepted use, including, but not limited to, preparations such as foot baths, nasal rinses, and mouthwashes. |
| <b>Required Medical Information</b> | Diagnosis, culture results showing presence of susceptible fungal elements.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an infectious disease specialist or other prescriber specializing in the organ system affected by fungal infection.  |
| <b>Coverage Duration</b>            | Initial - 3 mos. Recert: 3 mos if specialist attestation of need for prolonged duration of therapy.  |
| <b>Other Criteria</b>               | Covered for FDA approved indications. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements.                              |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# vowst

## Products Affected

- VOWST

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Must have a stool test positive for toxigenic <i>Clostridioides difficile</i> within the past 30 days.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | UNDER CMS REVIEW   |
| <b>Coverage Duration</b>            | One month.   |
| <b>Other Criteria</b>               | Covered for prevention of <i>Clostridioides difficile</i> infection (CDI) in patients who have had at least 2 recurrent episodes of CDI. Must have completed an antibiotic course for the treatment of CDI two to four days before initiation of treatment with Vowst. Patient must not be immune compromised. Retreatment with Vowst for the same CDI will not be covered. Vowst will not be covered for the treatment of active CDI. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# welireg

---

## Products Affected

- WELIREG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | UNDER CMS REVIEW   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an oncologist, urologist, nephrologist or provider who specializes in von Hippel-Lindau (VHL) disease.   |
| <b>Coverage Duration</b>            | 6 months   |
| <b>Other Criteria</b>               | Covered for treatment of advanced renal cell carcinoma in adults following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). Covered for patients with a diagnosis of von-Hippel-Lindau disease who have a confirmed germline VHL alteration and require therapy for one of the following: renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastoma, or pancreatic neuroendocrine tumor (PNET). Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# xdemvy

---

## Products Affected

- XDEMZY

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Microscopic examination of eyelashes showing Demodex mites.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an ophthalmologist.  |
| <b>Coverage Duration</b>            | Two months.  |
| <b>Other Criteria</b>               | Must have a diagnosis of Demodex blepharitis confirmed by microscopic examination of the eyelashes to detect Demodex mites. Must have bothersome symptoms of Demodex blepharitis (such as itchy eyelids, excessive eye tearing, light sensitivity, gritty or burning eye sensation). Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# xeljanz

## Products Affected

- XELJANZ ORAL SOLUTION
- XELJANZ ORAL TABLET
- XELJANZ XR

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an appropriate specialist to treat the stated diagnosis.  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for ANKYLOSING SPONDYLITIS (AS) in pts who have had serious side effects or drug failure w/ one of the following: Hadlima or Enbrel. TNF-blocker-experienced pts must have had serious side effects or drug failure with any AS-indicated TNF-blocker. Covered for POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS in pts who have had inadequate response or intolerance to methotrexate (MTX) or another disease-modifying anti-rheumatic drug (DMARD) and documented failure w/ one of the following: Enbrel or Hadlima. Covered for PSORIATIC ARTHRITIS (PsA) in pts who have had serious side effects or drug failure with either Hadlima or Enbrel. TNF-blocker-experienced pts must have had serious side effects or drug failure with any PSA-indicated TNF-blocker. Covered for active moderate to severe RHEUMATOID ARTHRITIS (RA) in pts who have failed to respond to or are intolerant of approved disease modifying anti-rheumatic drug (DMARD) agents, such as methotrexate, azathioprine, sulfasalazine, or hydroxychloroquine, either alone or in combination, for a 3-month period. In addition, the patient must have had serious side effects or drug failure with either Hadlima or Enbrel. TNF-blocker-experienced patients must have had serious side effects or drug failure with any RA-indicated TNF-blocker. Covered for moderately to severely active ULCERATIVE COLITIS (UC) who have had serious side effects or drug failure with Hadlima. TNF-blocker-experienced patients must have had serious side effects or drug failure with any UC-indicated TNF-blocker. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |

| PA Criteria                    | Criteria Details |
|--------------------------------|------------------|
| <b>Part B<br/>Prerequisite</b> | No               |



# xenazine

---

## Products Affected

- *tetrabenazine oral tablet 12.5 mg, 25 mg*

| <b>PA Criteria</b>                  | <b>Criteria Details</b>   |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | None  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# xermelo

## Products Affected

- XERMELO

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | For the treatment of carcinoid syndrome diarrhea, coverage will not be provided in the absence of concurrent somastatin analog therapy (lanreotide or octreotide).   |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an oncologist, hematologist, endocrinologist, or gastroenterologist.   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for the treatment of carcinoid syndrome diarrhea with documentation of continued diarrhea despite a minimum 3-month trial of somastatin analog therapy (lanreotide or octreotide). Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# xgeva

---

## Products Affected

- XGEVA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | Xgeva will not be approved for use in combination with oral or injectable bisphosphonates.  |
| <b>Required Medical Information</b> | Documentation of diagnosis. For a diagnosis of bone metastasis from solid tumor, provide radiographic evidence (X-ray, CT, or MRI) of a least one bone metastasis.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an oncologist.  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors for which there is radiographic evidence of at least one bone metastasis. Approved for treatment of giant cell tumor of the bone (in adults and skeletally mature adolescents) that is unresectable or where surgical resection is likely to result in severe morbidity. Approved for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |

# xhance

---

## Products Affected

- XHANCE

| <b>PA Criteria</b>                  | <b>Criteria Details</b>  |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | UNDER CMS REVIEW   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.       |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an allergist, immunologist, otolaryngologist, or pulmonologist |
| <b>Coverage Duration</b>            | For CRSwNP, initial approval 6 mos., recert every 1 yr thereafter.                   |
| <b>Other Criteria</b>               | UNDER CMS REVIEW   |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# xolair

---

## Products Affected

- XOLAIR

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | Xolair is excluded in patients weighing over 150kg. Xolair will not be covered for the treatment of atopic dermatitis. |
| <b>Required Medical Information</b> | Diagnosis, current and previous therapies used for the treatment of the stated diagnosis.                              |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an allergist, dermatologist, immunologist, otolaryngologist, or pulmonologist                    |
| <b>Coverage Duration</b>            | Initial approval - 6 months. Recertifications - 1 year.  |

| PA Criteria                | Criteria Details   |
|----------------------------|--|
| <b>Other Criteria</b>      | <p>Covered for the treatment of MODERATE TO SEVERE PERSISTENT ASTHMA. The patient must be maintained on asthma treatment consistent with the GINA or NHLBI guidelines, which recommend the combination of a high-dose inhaled steroid with a long-acting beta agonist (preferred by GINA guidelines), or leukotriene inhibitor, or long-acting muscarinic antagonist, or theophylline. For patients ages 12 and older, pt. must be experiencing asthma exacerbations and the patient must have baseline IgE levels between 30 and 700 iu/ml. For patients ages 6 to less than 12, must be experiencing asthma exacerbations and the patient must have baseline IgE levels between 30 and 1300 iu/ml. Patient must have documented evidence of at least 1 perennial aeroallergen (e.g., house dust mite [dermatophagoides farinae, d. Pteronyssinus], animal dander (dog, cat), cockroach, feathers, mold spores) by skin test or in vitro testing. Upon recertification, documentation should be provided validating reduction in asthma exacerbations. Covered for the diagnosis of CHRONIC IDIOPATHIC URTICARIA in patients that have experienced at least a six-month history of urticaria and the presence of hives associated with itching. In addition, the patient must have a documented history of symptomatic failure of H1 antihistamine treatment. Upon recertification, documentation should be provided validating response to therapy (such as decreased severity of itching, decreased size of hives, decreased number of hives). Covered for a diagnosis of NASAL POLYPS with documentation of inadequate response to 3-month trial of Xhance nasal spray and inadequate response with Nucala. Recertification will require documentation of continued use of intranasal corticosteroid and clinical benefit from Xolair use (e.g., reduced polyp size, improved nasal congestion, reduced sinus opacification, decreased sino-nasal sx, improved sense of smell). Covered for the treatment of IgE-MEDIATED FOOD ALLERGY in patients with single or multiple IgE-mediated FAs. Patient must have documented positive skin prick test, allergen-specific IgE, and/or oral food challenge included. Requests will also be evaluated for Part B vs Part D coverage and off-label use.</p> |
| <b>Indications</b>         | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>      |  |
| <b>Part B Prerequisite</b> | No   |

# yonsa

---

## Products Affected

- YONSA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results, current and previous therapies used for the treatment of the stated diagnosis  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by an oncologist or urologist.  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Covered for a diagnosis of metastatic castration-resistant prostate cancer. In addition, documentation of contraindication to both abiraterone and Xtandi (enzalutamide) must be provided. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |

# ztalmy

---

## Products Affected

- ZTALMY

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.   |
| <b>Required Medical Information</b> | Diagnosis, including supporting labs/diagnostic test results.   |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.  |
| <b>Prescriber Restrictions</b>      | Must be prescribed by or in consultation with a neurologist.  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Covered for the treatment of seizures associated with Cyclin-Dependent Kinase-Like 5 (CDKL5) deficiency disorder confirmed by CDKL5 genetic testing in patients 2 years of age and older. Recertification will require either (1) documentation of a sustained reduction in monthly seizure frequency compared to baseline or (2) subjective or objective evidence from provider that use of Ztalmy has improved the patient's condition. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.   |
| <b>Off Label Uses</b>               |   |
| <b>Part B Prerequisite</b>          | No  |



# zurzuvae

---

## Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Exclusion Criteria</b>           | As limited by FDA labeling.  |
| <b>Required Medical Information</b> | Diagnosis, pertinent diagnostic test results.  |
| <b>Age Restrictions</b>             | Patient age must be consistent with the FDA approval for the stated diagnosis.   |
| <b>Prescriber Restrictions</b>      | Must be prescribed by a psychiatrist, psychiatric nurse practitioner or an obstetrician-gynecologist.  |
| <b>Coverage Duration</b>            | 30 days.   |
| <b>Other Criteria</b>               | Covered for patients with a diagnosis of moderate to severe Postpartum Depression (PPD), based on an ACOG supported validated tool, such as Patient Health Questionnaire-9 (PHQ-9), Hamilton Rating Scale for Depression score (HAMD-17), Edinburgh Postnatal Depression Scale (EPDS). A maximum of 1 treatment course (14 days) will be allowed per a single postpartum period. Requests for non-FDA approved indications will be evaluated according to the Medicare statutory off-label use requirements. |
| <b>Indications</b>                  | All Medically-accepted Indications.  |
| <b>Off Label Uses</b>               |  |
| <b>Part B Prerequisite</b>          | No   |



## INDEX OF DRUGS

|  |     |   |     |
|--|-----|---|-----|
| <i>abiraterone</i> .....   | 101 | CAMZYOS.....  | 23  |
| ACTHAR.....  | 2   | CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG.....                               | 12  |
| ACTHAR SELFJECT.....   | 2   | CAPRELSA ORAL TABLET 100 MG, 300 MG.....                                      | 101 |
| ACTIMMUNE.....   | 3   | <i>carglumic acid</i> .....   | 24  |
| <i>adapalene topical cream</i> .....   | 147 | CERDELGA.....   | 26  |
| <i>adapalene topical gel 0.3 %</i> .....   | 147 | CHOLBAM.....  | 28  |
| ADEMPAS.....   | 116 | <i>chorionic gonadotropin, human intramuscular</i> ....                       | 29  |
| AJOVY AUTOINJECTOR.....  | 27  | <i>clomiphene citrate</i> .....   | 30  |
| AJOVY SYRINGE.....   | 27  | COMETRIQ.....   | 101 |
| AKEEGA.....  | 101 | COPIKTRA.....   | 101 |
| ALECENSA.....  | 101 | CORTROPHIN GEL.....   | 2   |
| ALTRENO.....   | 147 | COSENTYX (2 SYRINGES).....  | 31  |
| ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG.....   | 101 | COSENTYX PEN (2 PENS).....  | 31  |
| ALUNBRIG ORAL TABLET DOSE PACK.....  | 101 | COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML.....                               | 31  |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> .....   | 116 | COSENTYX UNOREADY PEN.....  | 31  |
| <i>amphetamine sulfate</i> .....   | 7   | COTELLIC.....   | 18  |
| <i>apomorphine</i> .....   | 8   | CUVRIOR.....  | 32  |
| ARAZLO.....  | 147 | DAURISMO ORAL TABLET 100 MG, 25 MG... ..                                      | 101 |
| ARCALYST.....  | 9   | DAYBUE.....   | 33  |
| ARIKAYCE.....  | 10  | <i>deflazacort oral suspension</i> .....                                      | 34  |
| <i>armodafinil</i> .....   | 132 | <i>deflazacort oral tablet 18 mg, 30 mg, 36 mg, 6 mg</i> .....                | 34  |
| <i>asenapine maleate</i> .....   | 12  | <i>dichlorphenamide</i> .....   | 77  |
| AUGTYRO.....   | 101 | <i>diclofenac sodium topical gel 3 %</i> .....                                | 4   |
| AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG.....   | 11  | DIFFERIN TOPICAL LOTION.....  | 147 |
| AUSTEDO XR ORAL 24-H ER TAB 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG.....                         | 11  | <i>dihydroergotamine nasal</i> .....  | 36  |
| AUSTEDO XR TITRATION KT(WK1-4) ORAL 24-H ER TAB DOSE PACK 12-18-24-30 MG, 6 MG (14)-12 MG (14)-24 MG (14)..... | 11  | DOJOLVI.....  | 37  |
| AUVELITY.....  | 12  | DOPTELET (10 TAB PACK).....   | 38  |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG.....  | 101 | DOPTELET (15 TAB PACK).....   | 38  |
| BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG.....   | 101 | DOPTELET (30 TAB PACK).....   | 38  |
| BENLYSTA SUBCUTANEOUS.....   | 14  | <i>doxepin topical</i> .....  | 39  |
| BESREMI.....   | 15  | <i>dronabinol</i> .....   | 40  |
| <i>bexarotene topical</i> .....  | 16  | <i>droxidopa</i> .....  | 41  |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> .....  | 116 | DUOBRII.....  | 146 |
| BOSULIF ORAL CAPSULE 100 MG, 50 MG....   | 101 | DUPIXENT SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML.....           | 42  |
| BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG.....  | 101 | DUPIXENT SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML.... | 42  |
| BOTOX.....   | 17  | ELIGARD.....  | 60  |
| BRAFTOVI.....  | 18  | ELIGARD (3 MONTH).....  | 60  |
| BRUKINSA.....  | 19  | ELIGARD (4 MONTH).....  | 60  |
| <i>budesonide rectal</i> .....   | 20  | ELIGARD (6 MONTH).....  | 60  |
| BYLVAY.....  | 21  | ELREXFIO.....   | 68  |
| CABLIVI INJECTION KIT.....   | 22  | ENBREL MINI.....  | 44  |
| CABOMETYX.....   | 101 | ENBREL SUBCUTANEOUS RECON SOLN.....   | 44  |
| <i>calcipotriene-betamethasone</i> .....   | 146 | ENBREL SUBCUTANEOUS SOLUTION.....   | 44  |
| CALQUENCE.....   | 19  | ENBREL SUBCUTANEOUS SYRINGE.....  | 44  |
|  |     | ENBREL SURECLICK.....   | 44  |
|  |     | ENSPRYNG.....   | 46  |
|  |     | ENSTILAR.....   | 146 |
|  |     | EPIDIOLEX.....  | 47  |

|   |     |   |     |
|---|-----|---|-----|
| ERIVEDGE.....   | 101 | ICLUSIG ORAL TABLET 10 MG, 15 MG, 30            |     |
| ERLEADA ORAL TABLET 240 MG, 60 MG.....                  | 48  | MG, 45 MG.....                                  | 101 |
| EVENITY.....  | 50  | IDHIFA.....                                     | 101 |
| <i>everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5</i>  |     | <i>imatinib oral tablet 100 mg, 400 mg.....</i> | 101 |
| <i>mg.....</i>  | 101 | IMBRUVICA ORAL CAPSULE 140 MG, 70 MG..          | 19  |
| <i>everolimus oral tablet for suspension 2 mg, 3</i>    |     | IMBRUVICA ORAL SUSPENSION.....                  | 19  |
| <i>mg, 5 mg.....</i>                                    | 101 | IMBRUVICA ORAL TABLET 420 MG.....               | 19  |
| EVRYSDI.....  | 51  | INBRIJA INHALATION CAPSULE,                     |     |
| FABIOR.....   | 147 | W/INHALATION DEVICE.....                        | 111 |
| FANAPT.....   | 12  | INCRELEX.....                                   | 66  |
| FASENRA PEN.....  | 52  | INGREZZA INITIATION PACK.....                   | 67  |
| FASENRA SUBCUTANEOUS SYRINGE 10                         |     | INGREZZA ORAL CAPSULE 40 MG, 60 MG,             |     |
| MG/0.5 ML, 30 MG/ML.....                                | 52  | 80 MG.....                                      | 67  |
| <i>fentanyl citrate buccal effervescent tab 200</i>     |     | INGREZZA SPRINKLE ORAL SPRINKLE CAP             |     |
| <i>mcg, 400 mcg, 600 mcg, 800 mcg.....</i>              | 110 | 40 MG, 60 MG, 80 MG.....                        | 67  |
| <i>fentanyl citrate buccal lozenge on a handle.....</i> | 110 | INLYTA ORAL TABLET 1 MG, 5 MG.....              | 101 |
| FILSPARI ORAL TABLET 200 MG, 400 MG.....                | 54  | INQOVI.....                                     | 101 |
| FINTEPLA.....   | 55  | INREBIC.....                                    | 101 |
| FIRDAPSE.....   | 56  | ISTURISA ORAL TABLET 1 MG, 5 MG.....            | 69  |
| FOTIVDA.....  | 101 | IWILFIN.....                                    | 101 |
| FRUZAQLA ORAL CAPSULE 1 MG, 5 MG.....                   | 101 | JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG,         |     |
| <i>gabapentin oral 24-h er tab 300 mg, 600 mg.....</i>  | 57  | 25 MG, 5 MG.....                                | 101 |
| GAMMAGARD LIQUID.....                                   | 71  | JAYPIRCA ORAL TABLET 100 MG, 50 MG.....         | 101 |
| GAMMAKED.....   | 71  | JOENJA.....                                     | 72  |
| GAMUNEX-C.....  | 71  | JUXTAPID ORAL CAPSULE 10 MG, 20 MG,             |     |
| GATTEX 30-VIAL.....                                     | 58  | 30 MG, 5 MG.....                                | 73  |
| GAVRETO.....  | 101 | JYNARQUE ORAL SEQUENTIAL TAB.....               | 74  |
| <i>gefitinib.....</i>                                   | 101 | JYNARQUE ORAL TABLET 15 MG, 30 MG.....          | 74  |
| GILOTRIF.....   | 101 | KALYDECO.....                                   | 75  |
| <i>glutamine (sickle cell).....</i>                     | 45  | KERENDIA.....                                   | 76  |
| GOCOVRI ORAL 24-H ER CAP 137 MG, 68.5                   |     | KEVZARA.....                                    | 78  |
| MG.....   | 111 | KISQALI.....                                    | 25  |
| HADLIMA.....  | 63  | KISQALI FEMARA CO-PACK ORAL TABLET              |     |
| HADLIMA (CITRATE-FREE).....                             | 63  | 200 MG/DAY(200 MG X 1)-2.5 MG, 400              |     |
| HADLIMA (CITRATE-FREE) PUSHTOUCH.....                   | 63  | MG/DAY(200 MG X 2)-2.5 MG, 600                  |     |
| HADLIMA PUSHTOUCH.....                                  | 63  | MG/DAY(200 MG X 3)-2.5 MG.....                  | 25  |
| HAEGARDA.....   | 115 | KOSELUGO.....                                   | 101 |
| HIZENTRA.....   | 126 | KRAZATI.....                                    | 101 |
| HUMIRA PEN.....   | 64  | <i>lapatinib.....</i>                           | 101 |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40                      |     | <i>lenalidomide.....</i>                        | 101 |
| MG/0.8 ML.....  | 64  | LENVIMA ORAL CAPSULE 10 MG/DAY (10              |     |
| HUMIRA(CF) PEN CROHNS-UC-HS.....                        | 64  | MG X 1), 12 MG/DAY (4 MG X 3), 14               |     |
| HUMIRA(CF) PEN PEDIATRIC UC.....                        | 64  | MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY           |     |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS.....                     | 64  | (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X         |     |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN                         |     | 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8      |     |
| INJECTOR KIT 40 MG/0.4 ML, 80 MG/0.8 ML...              | 64  | MG/DAY (4 MG X 2).....                          | 101 |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE                         |     | <i>leuprolide (3 month).....</i>                | 60  |
| KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4               |     | <i>leuprolide subcutaneous kit.....</i>         | 60  |
| ML.....   | 64  | <i>lidocaine topical patch 5 %.....</i>         | 79  |
| HYFTOR.....   | 65  | LIVMARLI ORAL SOLUTION 9.5 MG/ML.....           | 80  |
| HYQVIA.....   | 126 | LONSURF ORAL TABLET 15-6.14 MG, 20-             |     |
| IBRANCE.....  | 25  | 8.19 MG.....                                    | 101 |
| <i>icatibant.....</i>                                   | 5   | LORBRENA ORAL TABLET 100 MG, 25 MG..            | 101 |
|   |     | LUMAKRAS.....                                   | 101 |

|   |     |   |     |
|---|-----|---|-----|
| LUPKYNIS.....   | 81  | OMNITROPE.....  | 61  |
| LUPRON DEPOT.....   | 60  | ONUREG.....   | 101 |
| LUPRON DEPOT (3 MONTH).....   | 60  | OPSUMIT.....  | 116 |
| LUPRON DEPOT (4 MONTH).....   | 60  | OPSYNVI.....  | 116 |
| LUPRON DEPOT (6 MONTH).....   | 60  | OPZELURA.....   | 100 |
| LUPRON DEPOT-PED (3 MONTH)<br>INTRAMUSCULAR SYRINGE KIT 11.25 MG,<br>30 MG.....                 | 60  | ORENCIA (WITH MALTOSE).....   | 103 |
| LUPRON DEPOT-PED INTRAMUSCULAR KIT<br>11.25 MG, 15 MG, 7.5 MG (PED).....                        | 60  | ORENCIA CLICKJECT.....  | 103 |
| LUPRON DEPOT-PED INTRAMUSCULAR<br>SYRINGE KIT.....  | 60  | ORENCIA SUBCUTANEOUS SYRINGE 125<br>MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML.....  | 103 |
| LYBALVI ORAL TABLET 10-10 MG, 15-10 MG,<br>20-10 MG, 5-10 MG.....                               | 12  | ORENITRAM.....  | 116 |
| LYNPARZA.....   | 101 | ORENITRAM MONTH 1 TITRATION KT.....   | 116 |
| LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X<br>3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG<br>X 5)..... | 101 | ORENITRAM MONTH 2 TITRATION KT.....   | 116 |
| MAVYRET ORAL PELLETS IN PACKET.....   | 82  | ORENITRAM MONTH 3 TITRATION KT.....   | 116 |
| MAVYRET ORAL TABLET.....  | 82  | ORGOVYX.....  | 104 |
| MEKINIST ORAL RECON SOLN.....   | 18  | ORIAHNN.....  | 105 |
| MEKINIST ORAL TABLET 0.5 MG, 2 MG.....  | 18  | ORILISSA ORAL TABLET 150 MG, 200 MG....   | 106 |
| MEKTOVI.....  | 18  | ORKAMBI ORAL GRANULES IN PACKET.....  | 107 |
| <i>metformin oral 24-h er tab</i> .....   | 83  | ORKAMBI ORAL TABLET.....  | 107 |
| <i>methamphetamine</i> .....  | 84  | ORMALVI.....  | 35  |
| <i>mifepristone oral tablet 300 mg</i> .....  | 85  | ORSERDU ORAL TABLET 345 MG, 86 MG....   | 101 |
| <i>miglustat</i> .....  | 86  | OTEZLA.....   | 108 |
| <i>modafinil oral tablet 100 mg, 200 mg</i> .....   | 132 | OTEZLA STARTER ORAL TABLET DOSE<br>PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20<br>MG (4)-30 MG (47).....   | 108 |
| MOTPOLY XR ORAL 24-H ER CAP 100 MG,<br>150 MG, 200 MG.....                                      | 88  | OXBRYTA.....  | 109 |
| MYALEPT.....  | 89  | OZEMPIC SUBCUTANEOUS PEN INJECTOR<br>0.25 MG OR 0.5 MG (2 MG/3 ML), 0.25 MG<br>OR 0.5 MG(2 MG/1.5 ML), 1 MG/DOSE (4<br>MG/3 ML), 2 MG/DOSE (8 MG/3 ML)..... | 59  |
| MYTESI.....   | 90  | <i>pazopanib</i> .....  | 101 |
| NAMZARIC ORAL 24-H ER SPRINKLE CAP.....   | 91  | PEMAZYRE.....   | 101 |
| NAMZARIC ORAL 24-H ER SPRINKLE CAP<br>DOSE PACK.....  | 91  | PHESGO.....   | 68  |
| NERLYNX.....  | 101 | PIQRAY.....   | 101 |
| NINLARO.....  | 101 | <i>pirfenidone oral capsule</i> .....   | 112 |
| <i>nitisinone</i> .....   | 92  | <i>pirfenidone oral tablet 267 mg, 534 mg, 801 mg</i><br>.....  | 112 |
| NITYR.....  | 92  | POMALYST.....   | 101 |
| NOURIANZ.....   | 111 | PREGNYL.....  | 29  |
| NUBEQA.....   | 101 | PRIVIGEN.....   | 71  |
| NUCALA.....   | 93  | PROCRIT INJECTION SOLUTION 10,000<br>UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/ML,<br>3,000 UNIT/ML, 4,000 UNIT/ML, 40,000<br>UNIT/ML.....                        | 49  |
| NUEDEXTA.....   | 94  | PROCYSBI.....   | 113 |
| NUPLAZID.....   | 95  | PROLASTIN-C INTRAVENOUS SOLUTION.....   | 6   |
| NURTEC ODT.....   | 87  | PROMACTA ORAL POWDER IN PACKET<br>12.5 MG, 25 MG.....   | 114 |
| OICALIVA.....   | 96  | PROMACTA ORAL TABLET 12.5 MG, 25 MG,<br>50 MG, 75 MG.....   | 114 |
| OCTAGAM.....  | 71  | PYRUKYND ORAL TABLET 20 MG, 5 MG, 5<br>MG (4-WEEK PACK), 50 MG.....   | 117 |
| ODOMZO.....   | 101 | PYRUKYND ORAL TABLET DOSE PACK.....   | 117 |
| OFEV.....   | 97  | QINLOCK.....  | 101 |
| OGSIVEO ORAL TABLET 100 MG, 150 MG,<br>50 MG.....   | 101 | <i>quinine sulfate</i> .....  | 118 |
| OJEMDA.....   | 101 |   |     |
| OJJAARA ORAL TABLET 100 MG, 150 MG,<br>200 MG.....  | 101 |   |     |

|   |     |   |     |
|---|-----|---|-----|
| RADICAVA ORS STARTER KIT                                  |     | <i>tadalafil (pulmonary hypertension)</i> .....       | 116 |
| SUSPENSION.....   | 119 | <i>tadalafil oral tablet 2.5 mg, 5 mg</i> .....       | 138 |
| RECORLEV.....   | 120 | TAFINLAR ORAL CAPSULE.....                            | 18  |
| RELISTOR ORAL.....  | 99  | TAFINLAR ORAL TABLET FOR SUSPENSION                   | 18  |
| RELISTOR SUBCUTANEOUS SOLUTION.....                       | 99  | TAGRISSE.....   | 101 |
| RELISTOR SUBCUTANEOUS SYRINGE 12                          |     | TAKHZYRO SUBCUTANEOUS SOLUTION....                    | 115 |
| MG/0.6 ML, 8 MG/0.4 ML.....                               | 99  | TAKHZYRO SUBCUTANEOUS SYRINGE 150                     |     |
| RETACRIT.....   | 49  | MG/ML, 300 MG/2 ML (150 MG/ML).....                   | 115 |
| RETEVMO ORAL CAPSULE 40 MG, 80 MG...                      | 101 | TALZENNA.....   | 101 |
| RETEVMO ORAL TABLET 120 MG, 160 MG,                       |     | TARPEYO.....  | 140 |
| 40 MG, 80 MG.....   | 101 | TASIGNA.....  | 101 |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1                    |     | <i>tasimelteon</i> .....                              | 141 |
| MG, 2 MG, 3 MG, 4 MG.....                                 | 12  | <i>tavorole</i> .....                                 | 98  |
| REZLIDHIA.....  | 101 | TAVNEOS.....  | 142 |
| REZUROCK.....   | 121 | <i>tazarotene topical cream 0.1 %</i> .....           | 147 |
| RINVOQ ORAL 24-H ER TAB 15 MG, 30 MG,                     |     | <i>tazarotene topical foam</i> .....                  | 147 |
| 45 MG.....  | 122 | <i>tazarotene topical gel</i> .....                   | 147 |
| ROZLYTREK ORAL CAPSULE 100 MG, 200                        |     | TAZVERIK.....   | 101 |
| MG.....   | 101 | TEPMETKO.....   | 101 |
| ROZLYTREK ORAL PELLETS IN PACKET....                      | 101 | <i>teriparatide subcutaneous pen injector 20</i>      |     |
| RUBRACA.....  | 101 | <i>mcg/dose (620mcg/2.48ml)</i> .....                 | 143 |
| RYBELSUS.....   | 59  | <i>tetrabenazine oral tablet 12.5 mg, 25 mg</i> ..... | 161 |
| RYDAPT.....   | 101 | THALOMID ORAL CAPSULE 100 MG, 150                     |     |
| <i>sapropterin</i> .....                                  | 125 | MG, 200 MG, 50 MG.....                                | 145 |
| SCEMBLIX ORAL TABLET 100 MG, 20 MG,                       |     | TIBSOVO.....  | 101 |
| 40 MG.....  | 101 | <i>tolvaptan oral tablet 15 mg, 30 mg</i> .....       | 124 |
| SECUADO.....  | 12  | TRELSTAR INTRAMUSCULAR RECON SUSP.                    | 60  |
| SIGNIFOR.....   | 127 | <i>tretinoin</i> .....                                | 147 |
| <i>sildenafil (pulmonary hypertension) oral tablet</i> .. | 116 | TRIPTODUR.....  | 148 |
| SIMLANDI (CITRATE-FREE) AUTOINJECTOR                      |     | TRULICITY.....  | 59  |
| .....   | 128 | TRUQAP.....   | 101 |
| SIVEXTRO.....   | 129 | TUKYSA ORAL TABLET 150 MG, 50 MG.....                 | 101 |
| SKYCLARYS.....  | 130 | TURALIO ORAL CAPSULE 125 MG.....                      | 101 |
| SKYRIZI SUBCUTANEOUS PEN INJECTOR..                       | 131 | TYVASO.....   | 116 |
| SKYRIZI SUBCUTANEOUS SYRINGE 150                          |     | TYVASO INSTITUTIONAL START KIT.....                   | 116 |
| MG/ML.....  | 131 | TYVASO REFILL KIT.....                                | 116 |
| SKYRIZI SUBCUTANEOUS WEARABLE                             |     | TYVASO STARTER KIT.....                               | 116 |
| INJECTOR 180 MG/1.2 ML (150 MG/ML), 360                   |     | UPTRAVI ORAL TABLET 1,000 MCG, 1,200                  |     |
| MG/2.4 ML (150 MG/ML).....                                | 131 | MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400               |     |
| <i>sodium oxybate</i> .....                               | 133 | MCG, 600 MCG, 800 MCG.....                            | 116 |
| SOMAVERT.....   | 1   | UPTRAVI ORAL TABLET DOSE PACK.....                    | 116 |
| <i>sorafenib</i> .....                                    | 101 | <i>ursodiol oral capsule 200 mg, 400 mg</i> .....     | 149 |
| SPRYCEL ORAL TABLET 100 MG, 140 MG,                       |     | VALCHLOR.....   | 150 |
| 20 MG, 50 MG, 70 MG, 80 MG.....                           | 101 | VANFLYTA.....   | 101 |
| STELARA SUBCUTANEOUS.....                                 | 134 | VENCLEXTA ORAL TABLET 10 MG, 100 MG,                  |     |
| STIVARGA.....   | 101 | 50 MG.....  | 101 |
| <i>sunitinib malate</i> .....                             | 101 | VENCLEXTA STARTING PACK.....                          | 101 |
| SUNOSI ORAL TABLET 150 MG, 75 MG.....                     | 132 | VERKAZIA.....   | 151 |
| SYMDEKO ORAL SEQUENTIAL TAB 100-150                       |     | VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5                  |     |
| MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N)               |     | MG.....   | 152 |
| .....   | 136 | VERZENIO.....   | 25  |
| SYMPROIC.....   | 99  | VIJOICE ORAL GRANULES IN PACKET.....                  | 153 |
| SYNDROS.....  | 137 | VIJOICE ORAL TABLET 125 MG, 250                       |     |
| TABRECTA.....   | 101 | MG/DAY (200 MG X1-50 MG X1), 50 MG.....               | 153 |

|  |     |
|--|-----|
| VITRAKVI ORAL CAPSULE 100 MG, 25 MG ...  | 101 |
| VITRAKVI ORAL SOLUTION .....   | 101 |
| VIVJOA .....   | 154 |
| VIZIMPRO .....   | 101 |
| VONJO .....  | 101 |
| <i>voriconazole intravenous</i> .....  | 155 |
| VOWST .....  | 156 |
| VRAYLAR ORAL CAP, DOSE PACK .....  | 12  |
| VRAYLAR ORAL CAPSULE .....   | 12  |
| VYNDAMAX .....   | 139 |
| VYNDAQEL .....   | 139 |
| WELIREG .....  | 157 |
| XALKORI .....  | 101 |
| XDEMVI .....   | 158 |
| XELJANZ ORAL SOLUTION .....  | 159 |
| XELJANZ ORAL TABLET .....  | 159 |
| XELJANZ XR .....   | 159 |
| XERMELO .....  | 162 |
| XGEVA .....  | 163 |
| XHANCE .....   | 164 |
| XOLAIR .....   | 165 |
| XOSPATA .....  | 101 |
| XPOVIO ORAL TABLET 100 MG/WEEK (50<br>MG X 2), 40 MG/WEEK (40 MG X 1), 40MG<br>TWICE WEEK (40 MG X 2), 60 MG/WEEK (60<br>MG X 1), 60MG TWICE WEEK (120<br>MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG<br>TWICE WEEK (160 MG/WEEK) ..... | 101 |
| XTANDI ORAL CAPSULE .....  | 101 |
| XTANDI ORAL TABLET 40 MG, 80 MG .....  | 101 |
| YONSA .....  | 167 |
| ZEJULA ORAL TABLET 100 MG, 200 MG, 300<br>MG .....   | 101 |
| ZELBORAF .....   | 18  |
| ZOLINZA .....  | 101 |
| ZTALMY .....   | 168 |
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG,<br>30 MG .....   | 169 |
| ZYDELIG .....  | 101 |
| ZYKADIA .....  | 101 |